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ABSTRACT 
Despite being considered a disease of smokers, approximately 10-15% of lung cancer 
cases occur in never-smokers. Lung cancer risk prediction models have demonstrated 
excellent ability to discriminate cases from non-cases, and have been shown to be more 
efficient at selecting individuals for future screening than current criteria. Existing 
models have primarily been developed in populations of smokers, thus there was a need 
to develop an accurate model in never-smokers. This study focused on developing and 
validating a model using never-smokers from the Prostate, Lung, Colorectal, and Ovarian 
Cancer Screening Trial. Cox regression analysis, with six-year follow-up, was used for 
model building. Predictors included: age, body mass index, education level, personal 
history of cancer, family history of lung cancer, previous chest X-ray, and secondhand 
smoke exposure. This model achieved fair discrimination (optimism corrected c-statistic 
= 0.6645) and good calibration. This represents an improvement on existing never-
smoker models, but is not suitable for individual-level risk prediction.  
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CHAPTER I: INTRODUCTION 
One of the best-understood and described exposure-disease relationships is that of 
tobacco smoking and lung cancer. It is estimated that 85-90% of all lung cancer cases are 
attributable to tobacco smoke (Samet et al., 2009), although this statistic varies 
geographically and by gender. Relatively less attention has been paid to the other 10-15% 
of cases, those that occur in individuals who identify themselves as a “never-smoker”. 
With regards to lung cancer research, a never-smoker is an individual who reports 
smoking less than 100 cigarettes in their lifetime (Yang, 2011). While 10-15% of cases 
may not seem like an overwhelmingly large number, given the overall incidence of lung 
cancer in the population it still presents an important public health concern (Thun et al., 
2008). 
 Both epidemiologically and physiologically speaking, lung cancer in never-
smokers (LCINS) is considered a distinct disease from its counterpart in smokers, with a 
different set of risk factors (Sun, Schiller, & Gazdar, 2007). A number of different risk 
factors have been proposed, however the effect size and overall significance of each 
individual risk factor typically varies from study to study, and among different 
populations. Among the most consistently established risk factors are: secondhand smoke 
(SHS), occupational exposures (asbestos, silica), environmental exposures (radon), 
gender, family history of lung cancer, previous history of non-malignant lung disease and 
race/ethnicity (McCarthy, Meza, Jeon, & Moolgavkar, 2012; Rudin et al., 2009; 
Subramanian & Govindan, 2007).  
 The most common histological presentation of LCINS is as an adenocarcinoma, 
with estimates of between 47 and 76% of all cases (Subramanian, Velcheti, Gao, & 
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Govindan, 2007). This is a significant increase from the overall estimated 40% of all lung 
cancers (smokers and never-smokers) that are classified as adenocarcinoma (American 
Cancer Society, 2014). Additionally, never-smokers with lung cancer typically exhibit 
different molecular mutations than smokers’ lung cancers, with a higher frequency of 
Epidermal Growth Factor Receptor (EGFR) mutations. This has been linked to improved 
treatment through specific forms of therapy, specifically the use of EGFR inhibitors as 
part of a chemotherapy regimen (Rudin et al., 2009). While never-smokers or former-
smokers are typically diagnosed at an older age than current-smokers (68.7 years vs. 65.4 
years)(Tammemagi, Neslund-Dudas, Simoff, & Kvale, 2004), they demonstrate improved 
5-year survival (23% vs. 16%) (Nordquist, Simon, Cantor, Alberts, & Bepler, 2004).  
 Statistical predictive modeling has become common practice for lung cancer, as it 
has for a number of other cancers and illnesses. However to date there remains a lack of 
accurate predictive model specifically targeted at never-smokers. Beginning with Bach et 
al.(2003), many predictive models have demonstrated good ability for discerning 
individuals with cancer from those without, however the majority of these models have 
either focused solely on smokers, or included them along with former and never-smokers. 
Due to the overwhelming nature of smoking as a risk factor for lung cancer (OR >20 
when comparing current to never-smokers) (Clément-Duchêne et al., 2010), models 
including current or former smokers are often at risk of washing-out any effects of other 
predictors. Thus, the aim of this thesis was to develop and validate a risk prediction 
model for lung cancer in never-smokers, focusing on risk factors not related to active 
tobacco smoking, with the goal of correctly identifying individuals at the highest risk of 
developing the disease. 
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1.1 Lung Cancer in Never-Smokers as a Public Health Concern 
Lung cancer is the second most common neoplasm in both men and women in 
Canada and the United States (Howlader et al., 2011; Statistics Canada, 2015), with an 
estimate of 26,600 new Canadian cases in 2015 and 224,100 new American cases in 2014 
(American Cancer Society, 2014; Statistics Canada, 2015). Even conservatively 
estimating LCINS as 10% of all cases, this would mean approximately 2,600 new cases 
of lung cancer occurring in Canadian never-smokers and 22,000 new cases of lung cancer 
occurring in American never-smokers. Between 2007 and 2011, the National Cancer 
Institute’s Surveillance, Epidemiology and End Results (NCI-SEER) program reported 
the overall incidence of lung cancer as 60.0 new cases/100,000 person years (72.1 in 
males, 51.1 in females) (Howlader et al., 2011). This is slightly higher than the incidence 
of 51.9 new cases/100,000 person years (57.6 in males, 47.5 in females) reported by the 
Canadian Cancer Society in 2015 (Statistics Canada, 2015). Incidence rates for LCINS 
vary between cohorts and studies, however they are often similar to those of myeloma in 
men or cervical cancer in women (Wakelee et al., 2007). When considered a separate 
disease, LCINS would rank as the 7th leading cause of cancer-related death worldwide 
(Samet et al., 2009).  
1.2 Identifying and Screening High-Risk Individuals 
 Prognostic outcomes associated with lung cancer can be greatly improved by 
early detection. Of particular interest is the use of low-dose computed tomography (CT) 
scanning, which has demonstrated efficacy. When compared to radiography, CT scans 
have been shown to reduce lung cancer-specific mortality by 20% when included as part 
of a systematic screening program (Aberle et al., 2011). When detected early, lung cancer 
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has a reported 5-year survival rate of between 60 and 70%, however only approximately 
30% are detected at an early stage where surgery is still possible (Hocking et al., 2010). 
This demonstrates the importance of an effective screening strategy for lung cancer, as 
outcomes are drastically improved with earlier detection. 
 Screening the entire population is not a feasible option, both from a cost 
standpoint and a risk-benefit standpoint (Aberle et al., 2011). Thus, prediction models 
should be used to identify the subpopulation at the highest risk, those that are most likely 
to benefit from screening such as CT scans. A recent model, demonstrating good 
discrimination and calibration, was developed by Tammemagi and colleagues in 2013. 
This model estimates the six-year absolute risk for a given individual for developing lung 
cancer based on a number of risk factors; notably age, race, education level, body mass 
index (BMI), previous history of cancer, family history of lung cancer, diagnosis of 
chronic obstructive pulmonary disorder (COPD), and a number of predictors related to 
smoking status and intensity (Tammemagi et al., 2013). The authors claim that by 
screening the individuals with a six-year lung cancer diagnosis probability above 
approximately 0.0095, as identified by their model, they could correctly identify 90% of 
lung cancer cases for screening. To reduce cost or intervention-associated risk further, 
they estimate that 80% of cases could be identified by screening individuals above a 
0.0151 risk probability – the 65th percentile of smokers risk (Tammemagi et al., 2013).  
1.3 Risk Prediction Models & Gaps in Knowledge 
 To date, a number of risk prediction models have been developed with the goal of 
identifying high-risk individuals. Beginning with a model developed by Bach and 
colleagues (2003), risk prediction models have consistently demonstrated an ability to 
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predict 1-, 5- and occasionally 10-year risk of developing lung cancer. Many of these 
models looked at predictors such as age, gender, race, socioeconomic status (SES) and 
body mass index (BMI), as well as a number of different environmental and occupational 
exposures (Spitz et al., 2007; Tammemagi et al., 2011). However, due largely to the well-
known association between tobacco and lung cancer, the vast majority of predictive 
models contain a number of smoking-related predictors, such as duration and intensity. 
Given the overwhelming association of smoking and lung cancer (10-20x increased risk), 
other predictors such as radon or asbestos exposure may appear insignificant in a 
population including exclusively smokers, or a combination of smokers and non-smokers 
(Clément-Duchêne et al., 2010; Tammemagi et al., 2011).  
 Current risk prediction models focusing on never-smokers may be less than ideal 
for a number of reasons, particularly a lack of consistent information regarding risk 
factors aside from age and gender (McCarthy et al., 2012). Studies designed to look at 
associations between single risk factors – such as specific occupational hazards or 
exposures – and LCINS often have limited sample size and thus low statistical power 
(Hu, Mao, Dryer, & White, 2002; Lagarde et al., 2001). One study, by Spitz and 
colleagues (2007) stratified by smoking status and included never-smokers, however this 
model demonstrated only modest discrimination (Harrell’s c-statistic = 0.59). 
Furthermore, an ever-smoker model adapted and applied to never-smokers did not 
achieve the same level of discrimination as its ever-smoker counterpart (area under the 
curve (AUC) = 0.66 in never-smokers) (Tammemagi et al., 2014). Thus, there is a need to 
develop a risk prediction model in never-smokers that includes a wide range of variables 
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that improve prediction and demonstrates a higher degree of predictive performance – as 
measured by discrimination and calibration (to be discussed in a forthcoming section). 
1.4 Response to Gaps in Knowledge 
 In order to address the gaps in knowledge, research was conducted using data 
from the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. The 
PLCO screening trial is a large, randomized prospective screening trial, conducted by the 
National Cancer Institute (NCI), which recruited individuals aged 55-74 years. Included 
within this trial’s dataset are variables pertaining to cause and time of death (if deceased), 
diagnosis, staging and histopathology of different cancers, demographic information, 
anthropometric measures at different time points of life, family history of lung cancer, 
comorbidities and select medical histories. For this study, data were limited only to those 
individuals who identified themselves as “never-smokers”. Model building was 
accomplished using Cox survival analysis, with “lung cancer diagnosis” as the outcome 
variable. Predictors were included based on a priori knowledge of LCINS risk factors 
along with some exploratory investigation of novel variables – those that have not been 
included in previous models, such as ibuprofen usage - and hazard ratios (HRs) were used 
to determine the risk associated with each individual predictor. Internal validation was 
achieved using bootstrapping resampling methods. Descriptive statistics were used to 
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1.5 Study Aim 
 As was previously mentioned, the aim of this study was to develop and validate 
an accurate lung cancer risk prediction model in never-smokers. This was accomplished 
using high-quality data and sophisticated statistical modeling techniques. 
 The methodological approach consisted of using Cox survival analysis in Stata 13 
statistical software (StataCorp. 2013. Stata Statistical Software: Release 13. College 
Station, TX: StataCorp LP). Predictor variables were included via intelligent selection 
based on a priori knowledge of potential risk factors. Non-linear effects of continuous 
variables were modelled using multivariable fractional polynomials (MFPs) to better fit 
the true nature of the relationship. Discrimination (ability to identify an individual with 
cancer from an individual without) was evaluated using Harrell’s c-statistic, a measure of 
how well Cox models correctly identify individuals that have the outcome of interest. 
Calibration (agreement between expected and observed probabilities) was evaluated 
using Brier score, calibration plots and mean versus 90th percentile absolute error. 
Internal validation was conducted using bootstrapping methods to estimate the amount of 
over-fit to noise in the model. This study aimed to improve on previous models 
(Tammemagi et al., 2014) in a number of different ways. First, the PLCO dataset contains 
a larger number of LCINS cases than most other studies (n=276), as well as a large total 
number of never-smokers (n=69,272), which provided more statistical power than other 
studies. Also, through the use of MFPs, we aimed to more accurately model the 
relationship between individual predictors and the risk of developing lung cancer. 
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1.6 Conclusion 
 This thesis served to address an important gap in the literature and a public health 
need regarding LCINS. This predictive model intended to accurately discern never-
smoking individuals at the highest risk of developing lung cancer, and thus could provide 
justification for screening which may lead to early diagnosis and timely treatment. The 
efficacy of the Tammemagi (2013) model as a tool to identify high-risk groups has lent 
credence to the importance of developing a similar model specifically for never-smokers. 
Taking into account that LCINS is the 7th leading cause of cancer-related mortality 
worldwide (Samet et al., 2009), it is of importance that a predictive model is developed 
for this disease similar to those for breast cancer or overall lung cancer. For this reason, 
the development and validation of an accurate risk prediction model is an important step 
towards addressing LCINS as a public health concern. 
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CHAPTER II: LITERATURE REVIEW 
 In order to fully understand the importance and goals of this research, it is 
important to have a thorough grasp of work that has previously been done in this area. To 
begin, the biologic and histologic nature of lung cancer must be understood, including the 
pathologic mechanisms and different subtypes. Next, the burden of the disease on the 
population, both in general and specific to never-smokers, is detailed. A comprehensive 
examination of known and suspected risk factors for lung cancer in never-smokers 
(LCINS), including secondhand smoke (SHS), asbestos exposure, and family history of 
cancer, sheds light on the nature of potential predictors used to address the study aim. 
This is followed by an overview of research done in the field of lung cancer screening, 
particularly low-dose computed tomography (CT) scans, as they pertain to early detection 
and improved outcomes. Finally, the chapter concludes with a review of different 
predictive models which have proven effective. This provides evidence of the efficacy of 
lung cancer risk predictive modelling as a tool, as well as rationale behind the 
forthcoming Methodology section. Overall, this chapter should demonstrate the 
importance of the research aim, in addition to providing a basis for future chapters.   
2.1 Biology of Lung Cancer 
2.1.1 Etiology, Histology & Pathogenesis 
 Although often talked about as one disease, lung cancer is much more complex 
than that. Described by Sharma et al. (2007) as “a conglomeration of diseases of diverse 
etiology”, there is no singular pathway or mechanism associated with all forms of lung 
cancer. Carcinogenesis involves irregular cell growth, without proper cell death 
(apoptosis), with the possibility of invading other tissue (American Cancer Society, 
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2014). The typical pathway involves the activation of oncogenes or inactivation of 
tumour suppressor genes through the action of some exogenous or endogenous 
carcinogenic substance (chemicals in secondhand smoke, environmental toxins, human 
papilloma virus (HPV), etc.). Among the most commonly mutated genes associated with 
different types of lung cancer are Epidermal Growth Factor Receptor (EFGR) or KRAS, 
which act to control cell proliferation (Damjanov, 2012; Rudin et al., 2009) or tumour 
protein 53 (TP53), a tumour suppressor protein which helps to regulate gene expression 
(Shigematsu et al., 2005; Wakelee et al., 2007). This results in the uncontrolled and 
unregulated growth of cells resulting in the formation of tumours (Damjanov, 2012). 
Different mutations are more commonly associated with different subtypes of lung cancer 
(Carney, 1995), however the exact cause of many of these is not fully known (Damjanov, 
2012). 
 Lung cancer is classified into two broad types based on the histological nature of 
the tumour; small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC) 
(Hoffman, Mauer, & Vokes, 2000). NSCLC is further divided into the following sub-
types: adenocarcinoma, squamous cell carcinoma and large-cell carcinoma (Hoffman et 
al., 2000).  
2.1.1.1 Small-cell Lung Cancer 
 Defined by the World Health Organization (WHO) as “a malignant epithelial 
tumour consisting of small cells with scant cytoplasm” (World Health Organization, 
2004), SCLC account for approximately 13% of all lung cancers. The vast majority 
(~90%) of these cases occur in smokers (van Meerbeeck, Fennell, & De Ruysscher, 
2011). Surgical resection is typically not part of the normal course of treatment for 
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patients with SCLC, who instead undergo rounds of chemotherapy in order to slow the 
progression of the disease (Damjanov, 2012). Individuals with SCLC usually experience 
a quicker disease progression and poorer survival outcomes (Damjanov, 2012; van 
Meerbeeck et al., 2011). However, given the relatively low number of never-smokers 
who experience SCLC, most LCINS research tends to focus primarily on NSCLC 
(Subramanian & Govindan, 2007). 
2.1.1.2 Non-small-cell Lung Cancer 
2.1.1.2.1 Large-cell Carcinoma 
 Tumours classified as large-cell carcinoma are often centrally located within the 
lung, and are distinguished by poor differentiation. They are typically diagnosed based on 
the lack of any identifiers associated with SCLC, squamous-cell or adenocarcinoma 
(Damjanov, 2012; World Health Organization, 2004). Large-cell carcinoma are the least 
common of the three major NSCLC sub-types, accounting for approximately 10% of all 
lung cancer cases (Damjanov, 2012). In past studies, it has been shown to be less 
common among never-smokers than current or former smokers (Muscat & Wynder, 
1995), accounting for approximately 6.2% and 7.7% of all lung cancers in never-smoking 
males and females respectively. Large-cell carcinoma, like other NSCLCs, is typically 
treated with a combination of radiation and surgical resection at early stages, and 
radiation and chemotherapy at more advanced stages (Damjanov, 2012).  
2.1.1.2.2 Squamous-cell Carcinoma 
 Another centrally-located cancer is the squamous-cell carcinoma, which “start in 
early versions of squamous cells…flat cells that line the inside of the airways in lungs” 
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(American Cancer Society, 2014). Patients with squamous-cell carcinoma experience 
distant metastases less commonly than those with other types of lung cancer (World 
Health Organization, 2004). They account for 25-30% of all lung cancers, however they 
are much more common in smokers than non-smokers, as approximately 90% of cases 
are linked to tobacco smoking (American Cancer Society, 2014; World Health 
Organization, 2004). While squamous-cell carcinoma makes up a relatively large 
proportion of all lung cancers, a 2006 study by Toh et al. demonstrated that only 5.9% of 
all LCINS cases within their study population were of this variety (Toh et al., 2006). The 
typical course of treatment is similar to that of large-cell carcinoma, which is standard for 
all NSCLCs (Damjanov, 2012). 
2.1.1.2.3 Adenocarcinoma 
 Adenocarcinoma of the lung is a subtype consisting of tumours originating from 
secretory cells located in the epithelial lining of the lung. They typically grow slower than 
other types of NSCLCs, however metastases are more common than in squamous-cell 
carcinomas (American Cancer Society, 2014; World Health Organization, 2004). They 
are the most common form of lung cancer, accounting for approximately 40% of all cases 
(American Cancer Society, 2014; Damjanov, 2012). Despite already being the most 
common type overall, adenocarcinoma has been demonstrated to represent an even 
greater proportion of LCINS. Toh et al. (2006) found that adenocarcinoma represented 
69.9% of LCINS compared to just 39.9% of lung cancer in current smokers. 
Adenocarcinoma has a higher prevalence amongst women, individuals of East Asian 
descent, and younger populations (American Cancer Society, 2014). The increasing 
incidence amongst never-smokers has led to a number of studies examining the 
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mechanistic differences between carcinogenesis of adenocarcinoma in never-smokers, 
former-smokers and current smokers (Nordquist et al., 2004). Treatment for 
adenocarcinoma is standard for all NSCLCs (Damjanov, 2012), however recent studies 
have demonstrated positive response rates for EGFR tyrosine kinase (EGFR-TK) 
inhibitors (Rudin et al., 2009), as EGFR mutations have shown to be positively associated 
with adenocarcinomas in never-smokers (Rudin et al., 2009; Sharma et al., 2007). 
2.1.2 Clinical Features 
2.1.2.1 Symptoms 
 Damjanov (2012) broadly classifies lung cancer symptoms as being related to one 
of the following four things: “bronchial irritation or obstruction, local extension of the 
tumour into the mediastinum or pleural cavity, distant metastases, or systemic effects of 
the neoplasia.” According to the Canadian Cancer Society, symptoms that should lead to 
consulting a physician include a chronic, worsening cough, chest pain, wheezing, loss of 
appetite, frequent chest infections or blood in the sputum, amongst others (Canadian 
Cancer Society, 2014).  
2.1.2.2 Diagnosis 
 According to the American Cancer Society, “most lung cancers do not cause any 
symptoms until they have spread too far to be cured…”, indicating that by the time 
medical attention is sought, the cancer is already at a more advanced stage (American 
Cancer Society, 2014). Once identified, the diagnosis of cancer is made using 
bronchoscopy and associated brush or sputum cytology for centrally located cancers, and 
biopsy for peripheral cancers (World Health Organization, 2004).  It is estimated that 
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only approximately 10-15% of lung cancer patients are asymptomatic at diagnosis, 
having them detected during a routine chest X-ray (CXR) or similar examination 
(Damjanov, 2012). The majority of patients present with an advanced stage of the 
disease, at which point the prognosis is poor, and treatment often shifts towards 
management rather than curing (Midthun, 2013). Early stage NSCLC is associated with 
greatly improved 5-year survival rates following surgical resection (70% for Stage I vs. 
50% for Stage II), which highlights the importance of earlier diagnosis (Midthun, 2013). 
Lung cancer screening programs have been implemented with the goal of earlier 
detection and reduced mortality. The techniques and outcomes of lung cancer screening 
programs will be discussed in this thesis. 
2.1.3 Tumour Staging 
 Lung tumours are staged according to a number of anatomical features that are 
determined following the diagnosis of cancer. This staging is used to determine the extent 
of the cancer, while providing the physician with some guidance regarding treatment 
plans and the patients’ prognosis (National Cancer Institute, 2013). The most widely used 
system of tumour staging is the TNM system, which is currently on its 7th edition, and is 
developed by the Union for International Cancer Control (UICC) and the American Joint 
Committee on Cancer (AJCC) (National Cancer Institute, 2013). The TNM system uses 
three anatomic factors to assign the tumour to a stage group; the T – the size and local 
extension of the primary tumour, the N – the degree of metastases to regional lymph 
nodes, and the M – the presence of distant metastases (American Joint Committee on 
Cancer, 2010).  
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 These T, N and M classifications are used to group tumours into prognostic stage 
groups (Stage 0 – IV), with increasing group number corresponding to more extensive 
spread of the disease. Stage 0 is reserved for in situ carcinoma only, while Stages I-III 
correspond to varying degrees of large tumours, or those that have spread to surrounding 
lymph nodes or organs/tissues. Finally, Stage IV consists of cancers that have spread to 
distant organs or tissues, and thus have very poor prognosis (National Cancer Institute, 
2013). 
2.2 Descriptive Epidemiology 
 The effect of a disease on a population is accurately portrayed through effective 
presentation of epidemiological data – often a combination of multiple measures (Adami, 
Hunter, & Trichopoulos, 2008). Of these measures, the most pertinent to predictive 
modelling is incidence – new cases of a disease occurring over a specified time period. 
This allows for meaningful comparisons between different groups and populations, while 
focusing solely on the development of the disease, not the prognosis.  
2.2.1 Lung Cancer Statistics 
 We use statistics such as incidence and mortality rates in lung cancer research to 
determine the nature of the problem. That is, how pressing is the issue of lung cancer 
amongst the grand scheme of public health. Incidence rates from both the National 
Cancer Institute – Surveillance, Epidemiology and End Results (NCI-SEER) Program, 
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Table 1. Age-standardized lung cancer incidence rates (per 100,000 person-years) 






















Canada 2015 51.9 57.6 47.5 
Abbreviations: 
py = person-years 
NCI-SEER = National Cancer Institute – Surveillance, Epidemiology and End Results 
*NCI-SEER Standard Population: 2000 US Population, based off single-year ages in 2000 US Census 
†Canadian Cancer Society Standard Population: 1991 Canadian Population, based off five-year age groups 
  
Lung cancer is the second most common neoplasm in both men and women in the 
United States, trailing only prostate cancer in men and breast cancer in women (Howlader 
et al., 2011). The American Cancer Society projects 224,210 new cases of lung cancer in 
the United States in 2014, and an estimated 159,260 deaths from the disease; higher than 
the combined mortality from colon, breast and prostate cancers (American Cancer 
Society, 2014). While the second most common form of cancer, lung carcinoma accounts 
for the largest proportion of cancer deaths (American Cancer Society, 2014). 
 It has been estimated that between 10 and 15% of all lung cancers occur in never-
smokers (Samet et al., 2009). Even using a conservative estimate of 10% of cases and the 
American Cancer Society’s 2014 projection (American Cancer Society, 2014), this would 
result in approximately 22,000 new cases of lung cancer occurring in American never-
smokers. There has been a great deal of variability in incidence rates for LCINS, as 
shown by a 2007 study by Wakelee et al. (2007). Amongst different cohorts, incidence 
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rates ranged from 14.4 to 20.8 per 100,000 person-years in women, and from 4.8 to 13.7 
per 100,000 person-years in men (Wakelee et al., 2007). The cause of these discrepancies 
in differing cohorts can be attributed to a number of factors, including different 
timeframes, as well as differences in a number of different suspected etiologic factors 
(Wakelee et al., 2007). As is the case with most LCINS literature, the authors conclude 
that more research must be done on the etiologic factors associated with the disease. 
Nonetheless, when taken as a separate disease LCINS would rank as the 7th leading cause 
of cancer-related death worldwide (Samet et al., 2009). Incidence rates in the United 
States are similar to myeloma in men and cervical or thyroid cancer in women (Wakelee 
et al., 2007).  
2.3 Risk Factors 
 In order to develop a risk prediction model for LCINS, it is important to first gain 
an a priori understanding of which factors are suspected to contribute to the etiology of 
the disease. While current active smoking, as well as former smoking, is an 
overwhelmingly strong predictor of lung cancer (10-20x increased risk in current 
smokers, 7.5x increased in former smokers, both compared to never-smokers) (Clément-
Duchêne et al., 2010), a number of different potential demographic, lifestyle and other 
risk factors have been investigated with regards to their role in LCINS etiology (Samet et 
al., 2009). These different suspected risk factors will be discussed in the forthcoming 
section, in order to provide a basis for their potential inclusion as predictors in the model 
building stage of this thesis. 
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2.3.1 Modifiable Risk Factors 
 A number of the suspected risk factors for LCINS can be categorized as 
attributable to our everyday lives, or those that can be more readily changed. Henceforth 
in this thesis, they will be known as “modifiable risk factors”, as they are pertinent to an 
individual’s day-to-day activities and not predetermined in some way. For LCINS, these 
modifiable risk factors include: SHS exposure, occupational exposures, environmental 
exposures, BMI, hormone replacement therapy and dietary factors (Couraud, Zalcman, 
Milleron, Morin, & Souquet, 2012; McCarthy et al., 2012; Samet et al., 2009). Each of 
these risk factors, and their contributions to LCINS risk as outlined in literature, will be 
discussed in this upcoming section. 
2.3.1.1 Secondhand Smoke 
 In 1986, the United States Surgeon General’s report identified SHS as a cause of 
lung cancer in lifetime never-smoking adults (United States Department of Health and 
Human Services (USDHHS), 2006). In the 2006 report, which synthesizes results from a 
number of separate studies, it was concluded that there is sufficient evidence to suggest 
that SHS contains the same carcinogenic compounds as active tobacco smoking, and in 
concentrations great enough to cause lung cancer in lifetime never-smokers who were 
exposed (USDHHS, 2006).  
Results from the meta-analysis conducted as part of this report examined both the 
at-home and workplace effects of SHS on non-smoking individuals. Upon pooling data 
from a number of case-control and cohort epidemiological studies investigating spousal 
household smoking, a range of relative risk’s (RR’s) was 1.20-1.29, indicating a 
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significant risk associated with being a non-smoker living with an active-smoking spouse, 
when compared to a non-smoking spouse (USDHHS, 2006). The effect size remained 
consistent between men and women, and across a number of different study populations 
and geographic areas.  Similarly, for studies examining workplace exposure across a 
wide-range of populations, RR’s varied from 1.12-1.32 when comparing non-smokers in 
a workplace with SHS exposure, to those without. There was a noted dose-response 
relationship as well, corresponding to the intensity and duration of exposure, with a 3-
times greater risk experienced by those with the highest levels of exposure (>4 hours per 
day vs. no exposure) (USDHHS, 2006). The abundance of epidemiological evidence, 
coupled with the known biological carcinogenic characteristics of mainstream smoke 
(which composes approximately 85% of SHS), make SHS a strong risk factor for LCINS 
(Besaratinia & Pfeifer, 2008). 
2.3.1.2 Radon Gas 
 Radon gas is produced from uranium present in rocks and soil, which decays into 
active products capable of attaching to atmospheric particles, thus allowing it to be 
inhaled. Upon inhalation, it emits alpha radiation which damages epithelial cell DNA 
(Sun et al., 2007; US National Research Council, 1999), and is considered carcinogenic. 
Inhaled radon gas is considered the main source of radiation exposure for the general 
population, as it is ubiquitous in outdoor air in low concentrations while accumulating in 
higher concentrations in some indoor spaces (Lagarde et al., 2001; Sun et al., 2007). Long 
considered a major source of lung cancer amongst underground uranium miners, more 
recently evidence has arisen that residential radon levels may be present in high enough 
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concentrations to provide a significant risk (Krewski et al., 2005; US National Research 
Council, 1999).  
The Committee on the Biological Effects of Ionizing Radiation (BEIR) developed 
a model to determine the risk of residential radon concentrations, extrapolated from data 
obtained from studies on uranium miners coupled with typical indoor exposure levels 
(US National Research Council, 1999). They determined lifetime relative risks (LRRs) 
ranging from 1.19 to 7.01 from the lowest to highest exposure categories, indicating an 
apparent dose-response relationship. Furthermore, they suggested that in the United 
States an estimated 2,900 LCINS deaths per year can be directly attributable to residential 
radon exposure (Sun et al., 2007; US National Research Council, 1999). Finally, the 
American Cancer Society estimated that approximately 26% of all LCINS deaths are 
attributable to environmental radon (American Cancer Society, 2006), further indicating 
its role as an important risk factor. 
2.3.1.3 Indoor Air Pollution  
 The use of biomass in cooking and household heating has been identified as a 
potential risk factor for LCINS due to the carcinogenic nature of its by-products (Yang, 
2011). Coal smoke contains polycyclic aromatic hydrocarbons (PAH), which have known 
carcinogenic properties (Yang, 2011). Zhou and Christiani (2011) estimated that 13% and 
17% of all lung cancers in Chinese men and women respectively were attributable to 
indoor air pollution, primarily coal burning and cooking fumes (Zhou & Christiani, 
2011). The use of biomass for heating is especially prevalent in the developing world, 
with Reid et al. reporting that 74% of Indian, 67% of Nigerian and 81% of Kenyan 
households utilizing this method (Reid et al., 2012). This is a large population potentially 
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exposed to a risk factor for LCINS, which could lead to an increased incidence in the 
developing world.  Many studies, such as the 2007 meta-analysis by Sun et al. have 
indicated a high relative risk for exposure to cooking fumes (approximately 2.1), and for 
indoor biomass burning (approximately 2.66) (Sun et al., 2007). Most studies regarding 
indoor air pollution are conducted on East Asian populations, and relatively fewer exist 
for Europe and North America. However, one Canadian case-control study indicated an 
OR of 2.5 for women exposed to indoor cooking fumes compared to those who were not 
exposed (Ramanakumar, Parent, & Siemiatycki, 2007), and no increased risk for men. 
The association of lung cancer and cooking fume exposure in women is consistent across 
many studies, as they traditionally spend more time indoors and near cooking and heating 
sources than men (International Agency for Research on Cancer, 2012; Ramanakumar et 
al., 2007).  
2.3.1.4 Workplace & Occupational Environmental Hazards 
 Two of the predominant occupational and workplace hazards (SHS and radon) 
have already been discussed, so the forthcoming section looks at additional exposures 
suspected to be risk factors for LCINS. A third, and one that has been the subject of much 
discussion, is the occupational exposure to asbestos. While believed to be synergistic 
with cigarette smoking (Berman & Crump, 2008), other epidemiological studies suggest 
that exposure to occupational asbestos results in an increased lung cancer risk even 
among never-smokers. In their 2012 study, Villeneuve et al. determined an odds-ratio for 
men ever exposed to asbestos of 1.28, when compared to those who were never exposed. 
This was done while controlling for cigarette smoking, SHS and other occupational risk 
factors (Villeneuve, Parent, Harris, & Johnson, 2012). This study further supported the 
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evidence of a dose-response relationship, with the highest risk group corresponding to 
those with the greatest exposure (Villeneuve et al., 2012). While there is some variation 
in literature, small sample sizes, and limited information on specific occupations, there is 
generally enough information to conclude that occupational asbestos exposure serves as a 
risk factor for LCINS (Samet et al., 2009; Villeneuve et al., 2012).  
 There are a number of other occupational risk factors which have demonstrated an 
increased risk of lung cancer in literature, such as: silica (relative risk ranging from 1.6-
2.2), arsenic (odds ratio (OR) ranging from 2.6-5.1 compared to unexposed) and various 
other organic solvents and non-ferrous metal fumes (Samet et al., 2009). However, 
McCarthy et al. describe these exposures, and their accompanying lung diseases, as 
“rare” (prevalence <1/2,000) therefore do not provide a large attributable risk to the 
population (McCarthy et al., 2012) 
2.3.1.5 Hormone Replacement Therapy 
 There is a great deal of controversy in the literature about the associated risk of 
lung cancer in women taking hormone replacement therapy (HRT). HRT is an effective 
treatment for postmenopausal symptoms in menopausal females (Yao, Gu, Zhu, Yuan, & 
Song, 2013). In 1994, Taioli and Wylander, in their hospital-based case-control study, 
determined that estrogen replacement therapy (ERT), a common form of HRT, was 
significantly associated with adenocarcinoma (OR=1.7, 95% confidence interval 1.0-2.5, 
compared to those without ERT). When looking at only never-smoking women, there 
was found to be no significant relationship between ERT and lung cancer (OR=1.0, 95% 
confidence interval 0.3-3.8). 
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 In a 2010 study by Baik et al., which utilized data for 107,171 women from the 
Nurses’ Health Study, it was concluded that there was no increased risk of lung cancer 
associated with the use of post-menopausal hormones (Baik, Strauss, Speizer, & 
Feskanich, 2010). This population was predominantly current or former smokers, and 
thus provides differing findings to the aforementioned Taioli and Wylander study. While 
the Baik et al. study determined no increased risk of lung cancer in women with HRT, 
they did identify changes in histological type associated with use of this therapy, with a 
shift towards increased prevalence of adenocarcinoma (Baik et al., 2010).  
 A 2013 meta-analysis by Yao et al., which examined results for 656,403 subjects 
from 25 epidemiological studies spanning 24 years, found evidence of a protective effect 
for HRT among post-menopausal women (Yao et al., 2013). Across all the studies, an OR 
of 0.91 demonstrated a significant reduction in risk for women receiving HRT compared 
to those who did not (Yao et al., 2013). The reduction in risk was even greater in never-
smoking women, with an OR of 0.86 when compared to never-smoking women without 
HRT (Yao et al., 2013). Given the conflicting information in literature about the risk of 
lung cancer among women who underwent HRT, variables pertaining to occurrence or 
duration of this therapy will be examined for their role as potential predictors of LCINS.  
2.3.1.6 Body Mass Index 
 Body mass index (BMI), corresponding to height and weight in units of kg/m2, is 
commonly used in literature to distinguish individuals as underweight (BMI of less than 
18.5kg/m2), normal weight (BMI of 18.5-24.9kg/m2), overweight (BMI of 25-29.9kg/m2), 
or obese (BMI of at least 30kg/m2) (Dela Cruz, Tanoue, & Matthay, 2011; Renehan, 
Tyson, Egger, Heller, & Zwahlen, 2008). While increasing BMI is associated with 
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increased risk for many forms of cancer, this has not been the case for lung cancer. In a 
2008 meta-analysis, Renehan et al. examined the risk of a 5kg/m2 increase in BMI on 
various forms of cancer. Of the forms of cancer looked at (16 types in men, 19 in 
women), lung cancer was one of the few to have a protective relationship with increasing 
BMI; the others being esophageal squamous in both genders, and premenopausal breast 
cancer in women (Renehan et al., 2008). In the 13 studies- totalling 2,649,395 
participants- included in the meta-analysis, a lung cancer-specific relative risk of 0.76 in 
men and 0.80 in women demonstrated a significant protective effect associated with 
5kg/m2 increases in BMI (Renehan et al., 2008). 
 One likely cause of this protective association between high BMI and lung cancer 
risk is confounding due to smoking; that is, smokers typically have lower BMI and 
significantly higher lung cancer risks (Renehan et al., 2008). When separated by smoking 
status, the RR for a 5kg/m2 increase in BMI rose to 0.91 for never-smokers, and no longer 
demonstrated a significant protective effect (Renehan et al., 2008). In a 2007 study by 
Kabat et al., which stratified by smoking status, an increase in BMI was associated with 
an increased hazard ratio never-smokers. However small sample sizes led to wider 
confidence intervals and thus insignificant results for all BMI groups (Kabat, Miller, & 
Rohan, 2007).  
2.3.1.7 Diet 
 A number of studies have been conducted which investigate the effects of 
different foods, vitamins and minerals on the risk of lung cancer among both smokers and 
non-smokers. While the dietary intakes looked at have been variable, the most consistent 
protective effects seen in literature are with high vegetable and fruit intake (De Stefani et 
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al., 1999; Nyberg, Argenius, Svartengren, Svensson, & Pershagen, 1998; Voorrips et al., 
2000; Willett & Trichopoulos, 1996). In a 1999 case-control study, which investigated 
the potential protective effects of antioxidants on lung cancer risk, De Stefani et al. 
determined strong inverse relationships associated with carotenoids, Vitamins C and E, 
glutathione and flavonoids. Of particular note were carrots, spinach, and orange 
consumption, all of which were deemed to be significantly strongly protective 
(ORs=0.55, 0.69 and 0.54 when comparing highest versus lowest tertile of carrot, spinach 
and orange consumption respectively) (De Stefani et al., 1999). It has been demonstrated 
that there is a dose-response relationship between carrots and green, leafy vegetable 
intake and reduced risk of lung cancer. However, it may be difficult to discern this 
relationship from the “healthy lifestyle” effect; individuals who consume high amounts of 
green, leafy vegetables would typically partake in other protective or low-risk activities 
(Nyberg et al., 1998).  
 Long thought to be one of the main protective dietary factors, β-carotene was 
shown to have harmful effects in the β-Carotene and Retinol Efficacy Trial (CARET) 
(Omenn et al., 1996). This study, which included an active intervention of 500mg β-
carotene in addition to retinol, was stopped 21 months prior to intended completion due 
to significantly higher rates of lung cancer incidence and mortality among the 
intervention group compared to the control group (28% increase in lung cancer, 17% 
increase in mortality) (Omenn et al., 1996). In a follow-up study, carried through 
December 2001, it was found that lung cancer incidence was lower in the group that 
received the intervention than it was during the active-intervention period (RR=1.08 post-
intervention versus 1.28 during intervention, comparing intervention to placebo), 
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indicating a reduction of effects upon cessation of β-carotene/retinol supplementation 
(Goodman et al., 2004). The effects of β-carotene on lung cancer have been speculated to 
be strengthened by an interaction with smoking, and likely caused by the inhibition of 
apoptosis in pre-neoplastic cells (De Stefani et al., 1999; Goodman et al., 2004).  
2.3.2 Non-modifiable Risk Factors 
 As with many other diseases, there are a number of risk factors for LCINS that are 
beyond the scope of day-to-day activities of the individual. Unlike the modifiable 
predictors, these – henceforth known as “non-modifiable risk factors” – are less apt to be 
changed or influenced by a single intervention. They are more intrinsic to the individual. 
Among the non-modifiable risk factors most established for LCINS include age, gender, 
race/ethnicity, socioeconomic status, family history of cancer and a previous history of 
lung disease (Dela Cruz et al., 2011; McCarthy et al., 2012; Samet et al., 2009). Each of 
these risk factors will be discussed in the upcoming section. 
2.3.2.1 Age 
 Described by McCarthy et al. as “arguably the most important risk factor among 
never-smokers” (McCarthy et al., 2012), the influence of age on lung cancer risk has been 
observed consistently. While considered a “sufficiently rare” disease amongst individuals 
under the age of 40 (Samet et al., 2009), lung cancer incidence rates increase greatly as a 
person ages, and this trend has been demonstrated amongst populations of current, former 
and never-smokers (Meza, Hazelton, Colditz, & Moolgavkar, 2008). The trend of greatly 
increasing lung cancer incidence rates amongst older populations has been observed 
many times, amongst many studies and reviews (McCarthy et al., 2012; Meza et al., 
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2008; Samet et al., 2009; Thun et al., 2006) and is the most consistent predictor of LCINS 
risk. As such, its inclusion in predictive model building is necessary. 
2.3.2.2 Gender 
 When looking at the relationship between gender and LCINS, it important to 
remember that the never-smoking cohort is one that is dominated by women, particularly 
amongst older age groups. In a 2004 study by Nordquist et al., they observed 78% of the 
never-smoking cohort to be female, compared to just 54% in the smoking cohort 
(Nordquist et al., 2004). For this reason, it is important to interpret findings regarding 
LCINS gender differences with caution, as women represent a much larger at-risk 
population (Samet et al., 2009). Despite this, a 2007 meta-analysis by Wakelee et al., 
analysing the results of 6 large cohort studies, identified an increased incidence of LCINS 
among women than men (range of 4.8-13.7/100,000 person-years for men versus 14.4-
20.8/100,000 person-years for women) (Wakelee et al., 2007).  
 Although there is a higher incidence of LCINS among women than men, never-
smoking women have demonstrated better survival than men (age-standardized mortality 
rate 10.5/100,000 person-years among never-smoking men versus 8.9/100,000 person-
years among never-smoking women) (Thun et al., 2008). This aligns with the NCI-SEER 
data which identifies 5-year survival of 14.4% for men and 19.6% for women amongst all 
individuals with lung cancer relative to similar individuals without lung cancer 
(Howlader et al., 2011), which might suggest possible biological differences in lung 
cancer between genders. EGFR mutations are more prevalent in lung cancer in women, 
however this difference diminishes when adjusting for smoking status (Sagerup, 
Småstuen, Johannesen, Helland, & Brustugun, 2010). Despite this evidence of some 
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gender-based difference for LCINS and lung cancer in general, previous predictive 
models have found no significant effect of including a gender variable, indicating that it 
may in fact not be an important predictor (Tammemagi et al., 2011). 
2.3.2.3 Race/Ethnicity 
 As was the case with gender, careful consideration must be made when evaluating 
race or ethnicity as a predictor for LCINS. As has been noted in literature, it can be 
difficult to discern where risk attributable to a biologic race ends and risk attributable to 
cultural habits or other factors associated with that race begin (e.g. dietary habits, SES, 
etc.) (Zhou & Christiani, 2011). However, there have been a number of consistent trends 
noted regarding the relationship between race and LCINS, which warrant consideration 
as potential predictors.  
 In a 2008 meta-analysis, Thun et al. investigated the relationship between race 
and LCINS among 13 cohort and 22 cancer registry studies (Thun et al., 2008). When 
comparing to individuals of European descent, significant age-standardized effect 
estimates were seen with Asian men (RR=1.96), Asian women (RR=1.69), African 
American women (RR=1.34), while a non-significant estimate was seen for African 
American men (RR=1.33, 95% CI=0.9-2.1) (Thun et al., 2008). However, the same study 
also noted that lung cancer death rates for Asians living in the United States were more 
similar to those of European descent than Asians living in Korea or Japan (Thun et al., 
2008). This suggests that it is lifestyle factors associated with a certain race, and not the 
race itself, that may be responsible for the increased risk of LCINS in some populations. 
While having black race/ethnicity has been associated with a significant odds ratio in risk 
prediction models (OR=1.48), and lung cancer is shown to occur more frequently in 
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African American men (Haiman et al., 2006), incorporating “black men” versus other 
gender-race groups has not been shown to improve predictive model discrimination. This 
observation may be due to a modest number of black men in the PLCO sample, and a 
population that may not be representative of black men in general (Tammemagi et al., 
2011, 2013). The nature of this relationship further indicates that the association between 
race and LCINS, or lung cancer in general, is more due to the sum of different lifestyle 
factors than characteristics inherent to a specified race. Despite this, race may still be 
useful when included in a predictive model. 
2.3.2.4 Socioeconomic Status 
 Socioeconomic status - generally estimated as education level, income, 
occupation or living conditions (housing, environment) – represents an important 
contributing factor for a number of diseases, including LCINS. Ward et al. (2004) 
described socioeconomic factors as being “more important than biological factors” when 
describing their roles in cancer causation, going so far as to call poverty a carcinogen 
(Ward et al., 2004). This is due to the all-encompassing nature of SES. It influences so 
many areas of life: physical activity, occupational exposure, diet and access to proper 
health care, to name a few (Alberg, Brock, Ford, Samet, & Spivack, 2013; Ward et al., 
2004).  
 In a 2009 meta-analysis of 64 studies, Sidorchuk et al. broke SES into educational 
attainment, occupational categories and income level. Individuals in this meta-analysis 
were categorized by Socioeconomic Position (SEP), a multidimensional measurement 
including any of: educational attainment, occupation, income level and other social 
constructs that affect health in different ways (Sidorchuk et al., 2009). In this study, they 
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determined that while there is a strong association seen with a decrease in any of the three 
factors, and an increase in lung cancer risk, the most pronounced was seen with education 
attainment (Sidorchuk et al., 2009). There was a 65% increase in lung cancer risk when 
comparing the lowest to highest educational category, while a 33% increased risk was 
seen comparing the lowest to highest occupational category (of the three-level SEP 
categorical variables) (Sidorchuk et al., 2009). These effects remained consistent in both 
smoking-adjusted and unadjusted studies. In previous predictive models, education levels 
have been used as a surrogate for SES – with lower education associated with increased 
risk – and thus there is reason for its inclusion in data analysis and model building 
(Tammemagi et al., 2011). 
2.3.2.5 Previous History of Lung Disease 
 A number of lung and airway diseases have been implicated as potential causative 
agents for lung cancer, especially LCINS. The most commonly associated with LCINS 
are asthma, tuberculosis (TB) and pneumonia – while chronic obstructive pulmonary 
disorder (COPD) and emphysema appear strong only in smokers. While originally 
thought to be protective, due to an aversion to smoking, more recently asthma has been 
identified as a risk factor for lung cancer with the inflammation and inability to remove 
carcinogens from the airways serving as the likely causes (Fitzpatrick, 2001; McCarthy et 
al., 2012; Santillan, Camargo, & Colditz, 2003). In 2003, Santillan et al. performed a 
meta-analysis looking at the occurrence of lung cancer among asthmatics, both in never-
smokers and in populations adjusted for smoking status. In populations limited to never-
smokers, there was a fixed-effects relative risk (RR) of 1.8 (95% CI 1.3-2.3), while in a 
population containing current, former and never-smokers, controlling for smoking 
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history, there was an RR of 1.3 (95% CI 1.3-2.2) (Santillan et al., 2003). These consistent 
results, across multiple studies, are suggestive of asthma as a risk factor for lung cancer, 
particularly in a population of never-smokers (Santillan et al., 2003).  
 As was previously mentioned, two other lung diseases are thought to be risk 
factors for LCINS – TB and pneumonia. These diseases, which are both large sources of 
lung inflammation, have been known to expose cells to various carcinogenic compounds 
if the inflammation becomes chronic rather than acute (Fitzpatrick, 2001). The effects of 
TB and pneumonia, as well as COPD, chronic bronchitis and emphysema, were 
investigated in a 2011 meta-analysis by Brenner et al. This study, which restricted 
analysis to never-smokers so as to reduce confounding from smoking, determined 
significant positive associations between TB and pneumonia, and non-significant 
associations with COPD, emphysema and chronic bronchitis (RR=1.22, 95% CI 0.97-
1.53 compared to COPD/emphysema/chronic bronchitis-free) (Brenner, McLaughlin, & 
Hung, 2011). Among the never-smoking populations, significant RRs of 1.43 and 1.90 
were identified for pneumonia and TB respectively, when compared to controls (Brenner 
et al., 2011). While asthma, TB and pneumonia all have separate pathologies, 
inflammation is a common result, and thus a likely link between the three and the 
development of LCINS (Brenner et al., 2011; Fitzpatrick, 2001; Santillan et al., 2003). 
2.3.2.6 Genetic Mutations and Familial Aggregation 
 Through both family history studies, and genome association studies, there has 
been strong evidence of a familial contribution to the risk of lung cancer, particularly 
among populations of never-smokers (Rudin et al., 2009). A number of different genetic 
mutations have been identified by Genome Wide Association Studies (GWAS) as 
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potentially contributing to lung cancer risk, particularly among never-smokers (Rudin et 
al., 2009). Three loci in particular have shown to be associated with lung cancer: 5p15, 
6p21, and 15q25 (Brennan, Hainaut, & Boffetta, 2011). Loci 15q25 codes for three 
cholinergic nicotine receptors, which are known to be associated with nicotine, and thus 
is associated with tobacco addiction in smokers. However, inheriting at least two risk 
alleles on this loci is associated with an 80% increase in risk, and has been shown to be 
independent of smoking intensity (Brennan et al., 2011). Loci 5p15 contains two genes 
relevant for lung cancer, particularly the telomerase reverse transcriptase (TERT) gene 
which is considered vital to many forms of carcinogenesis (Brennan et al., 2011).  
 Familial aggregation of lung cancer is thought to be more than genetic heritability. 
It also represents the accumulation of shared exposures and habits (Matakidou, Eisen, & 
Houlston, 2005). In 2010, Lissowska et al. conducted both a large, multicentre case-
control study, and a meta-analysis, investigating the relationship between family history 
and cancer risk. When compared to individuals with no family history, there was a 
significant risk (OR=1.72, 95% CI 1.56-1.88) associated with having a first-degree 
relative with the disease (Lissowska et al., 2010). When restricted to only never-smokers, 
there is a reduced but still significant risk (OR=1.4 (95% CI 1.17-1.68)), indicating it is 
not simply a “habitual hereditary” relationship – smoking habits passed through 
generations (Lissowska et al., 2010). Overall, there is sufficient evidence to indicate a 
familial aggregation of lung cancer, both among the general population and when 
restricted to never-smokers, indicating its importance as a potential predictor for LCINS.  
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2.4 Lung Cancer Screening 
 While much of the focus on improving lung cancer outcomes is associated with 
primary prevention – smoking cessation strategies to stop the development of the disease 
– proper secondary preventative screening programs can also reduce mortality (van 
Klaveren, 2011). Approximately three quarters of all lung cancer cases are diagnosed 
following the onset of symptoms, at which point the disease has often progressed to a 
more advanced stage (Midthun, 2013). While the five-year survival for lung cancer is 
around 15% (van Klaveren, 2011), this is improved when successful surgical resection is 
completed. Among Stage IIA/IIB patients, five-year survival with resection is 
approximately 50%, and this improves to approximately 70% for Stage IA/IB cancers 
(Midthun, 2013). The improved survival and reduced mortality underscores the 
importance of detecting cancers at an earlier stage, where resection with curative intent is 
still possible, in order to improve prognosis. 
 Earliest forms of lung cancer screening began with chest radiography (CXR) in 
the 1960s-1970s, however a number of studies demonstrated no significant reduction in 
mortality (van Klaveren, 2011). Following the advent of low-dose computed tomography 
(LDCT) scanning in the early 1990s, there was an increase in lung cancer screening trials, 
most notably the National Lung Screening Trial (NLST), which ran from 2002 through 
2009 and compared LDCT to CXR (Aberle et al., 2011). This study provided the most 
conclusive evidence for the efficacy of LDCT as a screening tool for lung cancer. 
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2.4.1 Efficacy of Low-Dose Computed Tomography Screening 
 The NLST was a randomized-controlled trial consisting of three rounds of annual 
LDCT screening in the intervention arm, and three rounds of annual CXR in the control 
arm (Aberle et al., 2011). The study was focused entirely on “high-risk” individuals, 
those with a 30+ pack-year smoking history, between the ages of 55-74 and have recently 
(less than 15 years) quit smoking (Aberle et al., 2011). Among the intervention arm of the 
study, 24.2% of all screens were positive, and 39.1% of individuals had at least one scan 
considered suspicious of lung cancer (with a 96.4% false-positive rate upon further 
diagnostic evaluation). Meanwhile, the control arm contained 6.9% positive screens, with 
a 94.5% false-positive rate (Aberle et al., 2011). The key finding of the NLST was that, 
when comparing LDCT to CXR screening, there was an approximately 20% decrease in 
lung cancer mortality, and a 7% decrease in all-cause mortality (Aberle et al., 2011).  
 The reported values for LDCT include a positive-predictive value (PPV) ranging 
from 2.2% to 36%, and a negative-predictive value (NPV) of approximately 99% 
(Humphrey et al., 2013; van Klaveren, 2011). While the low PPV indicates a high 
number of false-positives, the follow-up testing is often non-invasive with minimal 
burden on the individual – thus this is an acceptable PPV range for lung cancer 
screening(Aberle et al., 2011). Based on their findings, a Number Needed to Screen 
(NNS) – the number of individuals needed to screen to prevent one lung cancer mortality 
– was estimated to be 320 (Humphrey et al., 2013; van Klaveren, 2011). This is a lower 
number than is currently seen in breast or prostate cancer screening (van Klaveren, 2011). 
 
	   	   	  	   	  35	  
2.4.2 Risks and Benefits of Low-Dose Computed Tomography 
Table 2. Risks and benefits of LDCT screening 
Adapted from (Wood et al., 2012) 
Risks Benefits 
Futile detection of small-aggressive 
tumours: metastasis happens too quickly to 
be caught by annual screening 
Decreased lung cancer mortality (20% 
among high-risk individuals as reported by 
the NLST) 
Anxiety associated with test results Improved quality of life: reduced morbidity 
and need for chemotherapy or radiation if 
cancer detected early. 
Physical complications from diagnostic 
workup 
Cost-effectiveness: $81,000 US per quality 
adjusted life year, below the threshold 
accepted for “reasonable value”. More 
cost-effective in high-risk groups (Black et 
al., 2014). 
High false-positive rate: 7% of false-
positive cases will undergo an unnecessary 
invasive procedure 
 
Cost: with approximately 7 million “high-
risk” individuals in the United States, 
screening costs are estimated at $2.1billion 
annually 
 
Radiation exposure: potential to cause 
further cancer/health complications 
 
 
2.4.3 Setting a Threshold: How Many People Do We Screen? 
 The NLST focused only on individuals they identified as being at the highest risk 
– current smokers, or those that have recently quit, between the ages of 55 and 74 years. 
However, it is not only this group that develops lung cancer. The key to maximizing 
screening effectiveness is identifying how many people we need to screen to detect the 
most cases while minimizing the number of false-positives. This is an important area of 
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healthcare research currently, as was identified by the NLST research team (Aberle et al., 
2011).  
 While the NLST uses their aforementioned “high-risk” criteria to determine who 
was eligible for LDCT screening, it is likely that this method results in many missed 
cases of lung cancer and includes many individuals at low risk of lung cancer. Similarly, 
the Centres for Medicare and Medicaid Services (CMS) in the United States recently 
approved coverage for LDCT screening for individuals between the ages of 55 and 77 
years, with a minimum 30 pack-year smoking history and either a current or recently quit 
(<15 years) smoker (CMS, 2015).  In Canada, there are currently no recommendations 
regarding LDCT screening (Bell, Dickinson, & Singh, 2014). In recent years, predictive 
modelling – which will be discussed in detail – has gained traction as a method for 
identifying individuals at the highest risk using a number of different variables and 
modelling features. Based on a previous predictive model, using a selected probability 
threshold, 90% of lung cancer cases that would develop within 6 years could be detected 
by screening 48.7% of the highest risk smokers (Tammemagi et al., 2013). Similarly, 
80% of cases could be identified by screening approximately the upper 35th percentile of 
highest risk individuals as identified by this model (Tammemagi et al., 2013).  
 In order for a screening program to be successful, it is important to carefully 
select who receives screening. This will identify as many cases as possible, while 
reducing the number of false-positives, maximizing the cost-effectiveness of screening 
(Aberle et al., 2011). Thus far, predictive modeling has been successful when applied to 
populations of smokers. However, to date, very little has been done to identify potentially 
high-risk never-smokers for LDCT, which is an area that will be addressed by this thesis. 
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2.5 Predictive Modelling 
 Predictive models for lung cancer have become increasingly common in recent 
years – used to complement clinical reasoning in modern medical decision making 
(Moons et al., 2012). While regression analysis can be done in a number of ways, such as 
for continuous outcomes, dichotomous outcomes or survival data (Vach, 2013), the focus 
on this section will be on modelling done for survival data– the time from the beginning 
of follow-up to the development of a disease, loss to follow-up, or censoring. 
 Predictive modeling uses a number of different covariates (predictors) to 
determine the probability (risk per unit time) that an individual will develop a specific 
outcome (Moons et al., 2012). These predictors can be any number of factors, from 
demographic characteristics such as age, gender or ethnicity, to clinical measurements 
such as blood pressure or the presence/absence of a specific biomarker (Moons et al., 
2012). There are a number of different ways that candidate predictors can be selected for 
the final model. This is often done through a combination of a priori knowledge of risk 
factors for the outcome of interest, as well as covariates that have demonstrated good 
predictive performance in previous models (Royston, Moons, Altman, & Vergouwe, 
2009). Two common methods of developing the final model from the set of candidate 
predictors are the full-model and multivariable (backward) selection approaches (Moons 
et al., 2012). Full-model uses all of the candidate predictors, and nothing else, and 
requires an extensive prior knowledge of the potential candidates for any given outcome. 
Multivariable selection begins with a full set of candidate predictors, and removes those 
that do not contribute to model performance (Moons et al., 2012). It is important not to 
exclude variables simply because of significance level, such as a p-value over a certain 
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threshold, as this can result in missing relevant predictors. (Harrell, Lee, Califf, Pryor, & 
Rosati, 1984; Moons et al., 2012). Conversely, choosing too many predictors (based on a 
high p-value), can result in model over-fitting (Moons et al., 2012). Over-fitting is a 
phenomenon that occurs in predictive models when the set of predictors becomes too 
specified to a given data sample (Royston et al., 2009). Predictors should be selected 
based on their contribution to predictive performance, not statistical significance. It is 
important to limit the number of predictors included in a model to allow for 
reproducibility on a new sample (Harrell et al., 1984), and thus a general rule of thumb is 
to have no more than one predictor for, at minimum, every 10 outcome events in the 
development sample (Moons et al., 2012). However, this number is not a concrete rule, 
and there has been shown to be limited risk associated with using between five and 16 
events per variable – especially in larger data sets (Vittinghoff & McCulloch, 2007). 
 Predictive performance of a model is assessed primarily through two ways: 
calibration and discrimination. Calibration is essentially how closely the model estimated 
probabilities agree with the observed probabilities (Moons et al., 2012). Discrimination 
relates to the models ability to distinguish those who experience the outcome from those 
who do not – correctly identifying a case from a non-case (Moons et al., 2012). 
Calibration and discrimination, as well as methods for evaluating them, will be discussed 
in sections 2.5.1 and 2.5.2. 
2.5.1 Calibration 
 In order for a model to potentially achieve individual-level prediction, it must 
achieve a high degree of calibration. Traditionally, this has been assessed either through 
calibration plots of observed versus mean predicted probabilities or through a goodness-
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of-fit statistic such as Hosmer-Lemeshow (p-value) (Moons et al., 2012). However, the 
Hosmer-Lemeshow statistic has shown to have limited power for assessing poor 
calibration (Royston et al., 2009). It has also shown significance with the addition of 
irrelevant predictors and at large sample sizes, falsely indicating poor calibration, and 
thus additional methods may be needed to accurately assess calibration. 
 One such statistic is the Brier score (Blattenberger & Lad, 1985; Brier, 1950; 
Murphy, 1972), roughly defined as:  .  
This means that, should an individual have an estimated probability of 0.75, and have the 
desired outcome (observed probability=1), they would contribute a score of 0.0625 to the 
overall Brier score (Brier, 1950). The Brier score can be broken down into components 
which can be used to measure calibration and discrimination, or be used to evaluate 
overall model performance. While there is no accepted range corresponding to “good” 
calibration, a lower score represents better agreement between estimated and observed 
probabilities, and a score of 0.25 is equivalent to chance. Another method of evaluation is 
the mean and 90th percentile absolute error, corresponding to the difference between the 
observed probability and the model-estimated probability (Tammemagi et al., 2011). It is 
critical to have good calibration, especially around decision-making risk threshold. 
2.5.2 Discrimination 
 Discrimination is often seen as the more important statistic when evaluating 
predictive models. It is argued that this is the case because without good discrimination, 
no amount of calibration can make a model accurate (Harrell et al., 1984). The most 
2(estimated probability - observed probability)
Number of observations
∑
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common method of evaluating predictive model discrimination is the receiving operating 
characteristic – area under the curve (ROC-AUC or AUC). Conceptually, it is the 
proportion of all informative pairings in which the individual with the outcome scores the 
higher risk from the model (Hanley & McNeil, 1982). In Cox regression models, the 
analogous concordance statistic (c-statistic) is used, providing similar values as the AUC 
(Harrell, 2001). With both the c-statistic and AUC, a higher value is considered a greater 
degree of discrimination. 
 Hosmer & Lemeshow (2000) outlined a general rule for classifying AUCs (and by 
extension c-statistics) by level of discrimination. Based on this, they define a score of 
≥0.9 as outstanding discrimination, between 0.8 and 0.9 as excellent discrimination and 
between 0.7 and 0.8 as acceptable discrimination. A score of 0.5 is no discrimination, 
equivalent to a coin flip (Hosmer & Lemeshow, 2000). According to Harrell (2001), an 
AUC of at least 0.8 is necessary if a model hopes to achieve acceptable individual level 
prediction.  
2.5.3 Previous Lung Cancer Prediction Models 
 A number of different risk prediction models have been developed for lung 
cancer, largely in populations of exclusively or largely smokers. A few notable models 
will be discussed in this section. 
2.5.3.1 Bach et al. 2003 Model 
 In response to previous models for breast cancer, Bach and colleagues developed 
the first multivariable model designed to predict lung cancer. This model was developed 
using the CARET study population, which enrolled both heavy current and former 
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smokers, as well as asbestos exposed men (Bach et al., 2003). Two separate 1-year 
models were developed using Cox proportional hazards regression: one for the 
probability of being diagnosed with lung cancer, and the other for the probability of dying 
from a competing cause. The models were cycled ten times to estimate 10-year risk. 
Predictors included in the model were age, gender, prior history of asbestos exposure, 
duration of smoking, average amount smoked per day, and duration of abstinence from 
smoking if a former smoker (Bach et al., 2003).  
 Internal validation was achieved through 10-fold cross-validation, while 
discrimination was assessed through the c-statistic and calibration through the evaluation 
of calibration plots (Bach et al., 2003). The calibration was determined to be excellent, 
while the c-statistic of 0.72 was in the range considered to be acceptable discrimination 
(Bach et al., 2003; Hosmer & Lemeshow, 2000). It was believed that the model is 
generalizable to other populations, however one main limitation was that it was restricted 
to only individuals over the age of 50 and with a history of smoking (Bach et al., 2003).  
2.5.3.2 Spitz et al. 2007 Model 
 This model, developed by Spitz and colleagues (2007), was designed to expand 
on previous work by including risk factors beyond just age, gender and smoking 
characteristics. It was developed using data from a large, matched case-control study 
(Spitz et al., 2007). Cases were recruited from a single-centre, while controls were 
referred from a different network. Cases and controls were matched based on age, gender 
and smoking status (current, former, never), with separate models developed and 
validated for each smoking strata (Spitz et al., 2007). Candidate predictors which 
achieved significance (<5%) in univariate analysis were considered for multivariable 
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logistic regression, and were then eliminated via backward selection to create the final 
models (Spitz et al., 2007). Each smoking strata was split into two components: 75% for 
training, and 25% for validation. Calibration was determined via Hosmer-Lemeshow 
goodness-of-fit, while discrimination was evaluated by AUC for the validation set and 
concordance statistic for the cross-validation sets (Spitz et al., 2007). 
 In the never-smokers model, SHS and dust exposure, as well as a family history 
of two or more first degree relatives with cancer were significantly associated with an 
increased risk of lung cancer (Spitz et al., 2007). In the former- and current-smoker 
models, additional exposures were included, as well as no history of hay fever and all 
variables related to smoking intensity and duration (Spitz et al., 2007). While the models 
all demonstrated good calibration based on the Hosmer-Lemeshow values – this has 
already been described as not being the best evaluation method – and none appeared to 
have good discrimination based on the concordance statistics: 0.59 in never-smokers, 
0.63 in current smokers and 0.65 in former smokers (Spitz et al., 2007). While one 
strength over previous models was the inclusion of never-smokers, there were a number 
of limitations as well. The data came from a case-control study, which increases 
susceptibility to selection and recall biases. Secondly, the study looked at only one ethnic 
group, and matched by age and smoking status – known risk factors for lung cancer 
(Spitz et al., 2007).  
2.5.3.3 Cassidy et al. 2008 Model 
 Another model developed from a case-control study was the Liverpool Lung 
Project (LLP) model, developed by Cassidy and colleagues. This study used subjects 
between the ages of 20-80 years, collected between the years 1998 and 2005, and age, 
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gender and smoking-matched with 2 controls (Cassidy et al., 2008). As with the Spitz 
model, univariate analysis was first used to determine significance at a 5% level, and all 
covariates with significance were then included in initial multivariable logistic regression 
(Cassidy et al., 2008; Spitz et al., 2007). This was followed with backward stepwise 
selection, with the removal of covariates if they did not reach 5% significance in the 
multivariable model (Cassidy et al., 2008). 10-fold cross-validation was performed, and 
discrimination was assessed using AUC (Cassidy et al., 2008).  
 In the final model, the following covariates demonstrated significantly increased 
risks: family history of lung cancer (especially if diagnosed before the age of 60), prior 
pneumonia diagnosis, prior cancer other than lung, occupational asbestos exposure, and 
duration of smoking (Cassidy et al., 2008). The AUC was 0.71, which indicates good 
ability to discriminate high- from low-risk individuals for this model (Cassidy et al., 
2008). The strengths of this model were that it compared well to previous models in 
terms of sensitivity and specificity, and included both the most important lung cancer risk 
factors (age, smoking) as well as a number of other suspected risk factors, however 
smoking was poorly used. It was a more detailed and included a wider range of predictive 
variables than the Spitz et al. (2007) model. Weaknesses of this model include those 
typical of a case-control derived model – high refusal rates and recall bias – as well as the 
need for further validation and limited external generalizability. Some of the predictors, 
such as asbestos exposure, require knowledge that may be too complex for use in a 
primary care setting. The reported AUC of 0.71 is on the low end of good discrimination, 
and may be inflated through the inclusion of never-smokers (Cassidy et al., 2008). 
Furthermore, the authors did not report any form of calibration for the LLP model. 
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Finally, while smoking is considered the strongest predictor of lung cancer, only one 
categorical predictor for smoking exposure was included – duration of exposure in 20-
year intervals (Cassidy et al., 2008).  
2.5.3.4 Tammemagi et al. 2011 Model 
 Using data from the PLCO randomized clinical trial, Tammemagi et al. (2011) 
developed a pair of models – one using the entire control arm, and one restricted to just 
current and former smokers in the control arm. A large number of predictors were 
considered for inclusion in the logistic regression model, with backward reduction at a 
significance level of 20% used to produce the final model (Tammemagi et al., 2011). 
Nonlinear effects of continuous variables were evaluated using restricted cubic splines. 
The overall model performance was evaluated using pseudo-R2, while discrimination and 
calibration were assessed using AUC (or c-statistic) and Hosmer-Lemeshow statistics 
respectively (Tammemagi et al., 2011). Correcting for optimism was performed using 
bootstrapping internal validation techniques and external validation was assessed using 
the PLCO intervention arm (Tammemagi et al., 2011). 
 In the full control arm model, the following predictors had significant associations 
with lung cancer: age, lower education, lower BMI, family history of lung cancer, 
presence of COPD, CXR in past 3 years, being a current smoker, pack years smoked and 
smoking duration (Tammemagi et al., 2011). The AUC was 0.859, while the calibration 
slope was 0.987, which indicates both excellent discrimination and calibration. Upon 
external validation in the intervention arm, discrimination remained high (c-
statistic=0.857) (Tammemagi et al., 2011). In the ever-smoker model, significant 
predictors were age, pack years and duration of smoking, while risk decreased with 
	   	   	  	   	  45	  
increasing quit time (Tammemagi et al., 2011). As with the full control arm model, 
discrimination and calibration were both excellent (AUC=0.809, optimism-correct c-
statistic=0.805 calibration slope=0.979) (Tammemagi et al., 2011). These models 
improved on previous prediction models through both the inclusion of new predictors and 
the use of nonlinear effects for evaluating continuous variables. Additionally, using 
prospective data allows for the estimation of incidence and absolute risk directly while 
avoiding the biases associated with case-control data (Tammemagi et al., 2011).  
 Using PLCO data, an ever-smoker model was modified to be applicable to the 
NLST population, which demonstrated excellent to good discrimination in the 
development and validation samples (AUC 0.803 and 0.797, respectively) (Tammemagi 
et al., 2013). This model, referred to as the PLCOm2012 compared positively to the 
NLST selection criteria (Aberle et al., 2011), indicating that this model may be suitable 
for individual-level recommendation for screening (Tammemagi et al., 2013). An 
analogous model, PLCOall2014, was developed in the PLCO control arm ever- and never-
smokers. This model achieved excellent discrimination in the PLCO intervention arm, but 
did not perform as well when limited to only never-smokers (Tammemagi et al., 2014). 
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CHAPTER III: METHODS 
 This chapter describes the methods and design of the study. It begins by 
discussing the overall study design of the PLCO randomized screening trial, including 
ethical considerations, recruitment, methods of obtaining consent as well as the 
randomization and screening processes, follow-up measures and methods of data 
collection and reporting. It then transitions to the design of this specific study, including 
the statistical methods chosen for model building, preliminary data analysis, variable 
selection, and methods for evaluating the completed model. 
3.1 Source Data – PLCO Randomized Screening Trial 
 The design of the PLCO has been described in previous studies (Oken et al., 
2011; Prorok et al., 2000). Conducted by the National Cancer Institute, this multicentre, 
two-arm, randomized trial was designed to examine the effectiveness of screening 
methods for prostate, lung, colorectal and ovarian cancers compared to standard medical 
care (Prorok et al., 2000). The pilot stage was initiated in 1993, with main study 
recruitment beginning in 1994 and carrying on until 2001 (Oken et al., 2011; Prorok et 
al., 2000). Additional follow-up is still ongoing, with expected completion in 2015 
(Prorok et al., 2000).  
3.1.1 Study Centres & Ethical Considerations 
 The PLCO used a multicentre approach, with ten centres scattered across the 
United States, with each centre responsible for recruiting between 5,000 and 30,000 
individuals from their surrounding areas (Prorok et al., 2000), for an estimated total of 
~37,000 males and ~37,000 females in each of the study arms. Each institution was 
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responsible for obtaining annual institutional board approval for the conduct of the study 
(Oken et al., 2011). The methods for obtaining consent from individual participants will 
be discussed in more detail in section 3.1.3. 
3.1.2 Recruitment 
 Participants were recruited from a variety of sources, all on a volunteer basis, with 
each study centre responsible for their individual recruiting practices (Prorok et al., 
2000). Primary recruitment was achieved via mass mailing, and ethnic diversity was said 
to be reflective of the diversity of each individual study centre (Oken et al., 2011), with 
minority representation sought “in appropriate numbers” (Prorok et al., 2000).  
 Participants were excluded from the study if they had a history of any of the 
PLCO cancers, were currently undergoing treatment for cancer, had surgical removal of 
the entire colon, one lung or the entire prostate, had undergone recent screening tests, 
were outside of the 55-74 age range at the time of study entry, or were unwilling or 
unable to sign the consent form (National Cancer Institute, 2014; Prorok et al., 2000).  
3.1.3 Consent 
 Patients were informed of any discomforts and risks associated with the screening 
procedures, the risk of falsely identifying cancer and were notified that diagnosis and 
treatment following screening would not necessarily extend a persons life (Prorok et al., 
2000). Consent was received from each participant prior to randomization into the trial. 
The consent form was approved by the NCI, as well as the National Institutes of Health 
(NIH) – Office for Protection from Research Risks and the United States Office of 
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Management and Budget (Prorok et al., 2000). Each study centre also received approval 
from their respective institutional review board (Prorok et al., 2000). 
3.1.4 Randomization and Screening 
 Upon entry into the study, baseline information regarding demographics, medical 
history, smoking history and past screening was obtained via a structured epidemiological 
questionnaire (Oken et al., 2011). Block randomization was utilized to randomize 
participants to the intervention or control arms, stratified by study centre, gender and age 
(Oken et al., 2011; Prorok et al., 2000). Individuals assigned to the screening arm were to 
receive CXR for lung cancer, in addition to screening tests for colorectal, prostate (if 
male), and ovarian (if female) cancers (Prorok et al., 2000). At the time of randomization, 
an additional dietary questionnaire (DQX) was offered to participants in the intervention 
arm, and 82% were completed (National Cancer Institute, 2014).  
 In total, 154,901 participants were randomized, with 77,445 entering the 
internvetion arm and 77,456 entering the control arm (Oken et al., 2011). Individuals in 
the screening arm received baseline and three annual rounds of CXR taken by a qualified 
technologist and interpreted by a radiologist (Prorok et al., 2000), while those in the 
control arm continued to receive standard medical care. Never-smokers randomzied post-
April 1995 received only two follow-up CXR exams (Prorok et al., 2000). An 
examination was considered positive if it contained any of a number of abnormalities 
suspicious of lung cancer, as determined by a radiologist (Prorok et al., 2000).  
 
 
	   	   	  	   	  49	  
3.1.5 Diagnostic and Therapeutic Follow-up 
 Individuals with positive screening results were notified, and referred to a 
physician of their choosing for appropriate follow-up (Prorok et al., 2000). While the 
PLCO protocol does not describe specifications for diagnosis and therapy, participants 
with a positive screening result were recommended to seek appropriate medical follow-up 
including diagnosis and, if required, treatment (Prorok et al., 2000). All treatment was 
expected to be in accordance with currenct accepted practice for stage of cancer, age, and 
overall medical condition of the participant (Prorok et al., 2000). Along with screening 
tests, all complications resulting from diagnostic or therapeutic follow-up were recorded 
(Prorok et al., 2000). 
3.1.6 End Points 
 The primary endpoints for the PLCO screening trial were cause-specific mortality 
for each of prostate, lung, colorectal, and ovarian cancers (Prorok et al., 2000). Secondary 
endpoints include incident cases of cancer, stage shift, and case survival (Prorok et al., 
2000). Information regarding the any-site diagnosis of cancer as well as all deaths 
occuring during the trial were obtained by annual study update questionnaires, and 
follow-up phone calls if necessary (Oken et al., 2011) while end-points were verified 
through linkage to the National Death Index (NDI) (Oken et al., 2011).  
3.1.7 Data Recording and Follow-up 
 All prevalent and incident PLCO cancers, and cause-specific deaths that occur 
during follow-up were ascertained by an active follow-up process and supplemented 
through usage of cancer registries if such data were available to each individual study 
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centre (Prorok et al., 2000). Participant information was recorded for the following: 
identification number, demographic and risk factor information, randomization group, 
date of birth and date of entry, results of each screening test including any complications, 
sufficient information on any diagnostic follow-up, any PLCO cancer diagnosed during 
follow-up and information regarding histology and stage at diagnosis, and every death – 
time and cause – occurring in both trial arms (Prorok et al., 2000). In this study, all 
personal identifiers (date of birth, date of death) have been removed to ensure anonymity. 
 A total of 13 years of follow-up was conducted for each participant who was not 
diagnosed with cancer or lost to follow-up in both the intervention and control arms, with 
an estimated completion in 2015 (Prorok et al., 2000). In 2006, a supplemental 
questionnaire (SQX) was sent to any remaining study participants. This questionnaire 
collected overlapping information with what was collected at baseline, as well as new 
information pertaining to some occupational exposures, physical activity, history of 
asthma, and SHS (National Cancer Institute, 2014). 
3.2 Risk Prediction Model Development and Validation 
 This upcoming section discusses the methods for model building from the initial 
stages through completion and validation. Topics include the choice of statistical 
methods, candidate predictor selection, data maintenance, as well as the model building 
and evaluation, and methods for validating the model. 
3.2.1 Sample Data 
 Data for this study came from the aforementioned PLCO randomized screening 
trial, utilizing six-years of follow-up of never-smokers in both the intervention and 
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control arms. This was done to develop a comparable model to those by Tammemagi et 
al. (Tammemagi et al., 2013, 2014). The PLCO contains 69, 272 never-smokers, among 
which there were 276 cases of lung cancer (109 occurring in the six-year follow-up) – 
representing one of the largest never-smoker cohorts analyzed to date. 
3.2.2 Statistical Methods 
 Since the study contains both a dichotomous outcome measure and time-to-event 
data, Cox proportional hazards regression was the best choice for statistical methodology 
for the predictive model (Cox, 1972). The outcome measure was lung cancer incidence 
(yes or no) at any point during the study period – screening or follow-up up to six years. 
Time-to-event data were the time from randomization to the incidence of lung cancer, or 
until the six-year cap or time to lost to follow-up in those without the disease. All 
preliminary variable analysis, data maintenance, model building and evaluation were 
performed using Stata 13 Statistical Software (StataCorp. 2013. Stata Statistical 
Software: Release 13. College Station, TX: StataCorp LP) and the rms package in R-
statistical software (Harrell, 2014). 
3.2.3 Candidate Predictors 
 Candidate predictors were chosen based on a priori knowledge of LCINS risk 
factors - those described in the literature review, combined with variables that have 
demonstrated good predictive ability in previous models. The variables preselected as 
candidate predictors include the following demographic risk factors: age, gender and 
race/ethnicity, and education level (six-level categorical) (Tammemagi et al., 2011). 
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Body mass index, measured in kg/m2, was considered as a potential protective predictor 
for LCINS. 
 History of COPD, chronic bronchitis, and emphysema were all considered as they 
pertain to previous history of lung diseases. A number of variables were considered 
regarding family history – lung cancer incidence in father, mother, sibling or child – as 
well as the age at which these individuals were diagnosed. Receiving a CXR in the three 
years prior to baseline was also considered, as it has demonstrated an increased risk of 
lung cancer in previous models (Tammemagi et al., 2011). Three variables were 
investigated to address the conflicting literature regarding the association of female 
hormones and LCINS: is the individual currently taking female hormones (yes vs. no), 
have they ever taken them (yes vs. no) as well as the age of onset of menopause (<40 vs. 
40+). Variables pertaining to dietary intake – particularly fruits and vegetables – and 
physical activity were investigated. Finally, SHS exposure was evaluated using three 
variables from the supplemental questionnaire: household smoking prior to age 18 years, 
household smoking after the age of 18 and indoor workplace smoking, all of which are 
dichotomous (yes vs. no) variables. Given the limitations of previous models in never-
smokers, novel predictors were investigated to potentially improve predictive 
performance. Limited exploratory analysis was conducted for some suspected – but less 
established – risk factors for lung cancer, such as past ibuprofen use (Endo, Yano, 
Okumura, & Kido, 2014). 
 A number of predictors could not be included, despite known or suspected 
association with LCINS, due to limitations in the comprehensiveness of the PLCO data 
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collection. Risk factors that could not be considered as candidates include radon 
exposure, asbestos and other occupational exposures, and indoor air pollution.  
3.2.4 Data Preparation and Maintenance 
 Prior to regression modelling, individual predictors were separately evaluated for 
missing data, as well as potential outliers. Outliers were investigated using boxplots, with 
outliers defined as values 3-times the interquartile range (25th-75th percentile) above the 
75th percentile or below the 25th percentile (Steyerberg, 2009). However, the PLCO 
utilized Information Management Services to ensure clean data, and thus minimal 
cleaning was required. Measures of central tendency were calculated to determine the 
spread of continuous variables. To examine differences in descriptive statistics between 
individuals with lung cancer and those without, Wilcoxon rank-sum test was used for 
non-normally distributed continuous variables and Pearson’s chi-square test or Fishers 
exact test were used for categorical variables. 
3.2.4.1 Multiple Imputation 
 Variables with a large amount of missing data, such as those from the Dietary and 
Supplemental questionnaires, were imputed to maximize the number of observations 
included in the final model. Data can be missing in one of three ways: missing 
completely at random, missing at random, or missing not at random (White, Royston, & 
Wood, 2009). Missing data in the PLCO data set was determined to be missing at random 
through the use of the patterns function in Stata as well as consideration for the cause of 
the missingness. Data for these variables was missing for a reason (participants did not 
complete the questionnaires), however this was not related to the variables themselves. 
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Missing at random allowed the missing-ness to be handled through multiple imputation 
(White et al., 2009). Due to the many types of variables being imputed, multiple 
imputation by chained equations (MICE) was chosen as the optimal method. MICE 
allows for simultaneous handling of continuous and categorical variables, and even non-
normally distributed continuous data (White et al., 2009).  
 Ten imputations were chosen, as it provided a large enough number to avoid 
skewed estimates, while still allowing completion in a reasonable timeframe (White et al., 
2009). Previous history of cancer, CXR in the past three years, ibuprofen usage, and the 
SHS variables (as a child, workplace, and as an adult) were imputed as logit variables. 
Family history of lung cancer, education level, and marital status were imputed as 
multilevel-logit variables. Drinks per week and BMI were imputed using predictive mean 
matching, a method of imputing non-normally distributed continuous variables. Finally, 
age, gender and lung cancer diagnosis were used as predictors in addition to the 
aforementioned imputed variables, but not imputed as they did not contain missing data. 
The effects of variables in the final model were then combined from each imputation, as 
was allowed by Rubin’s rules (D. B. Rubin, 1987). 
3.2.5 Model Building 
3.2.5.1 Handling Continuous Predictors 
 The continuous predictors considered for the final prediction model, age and BMI, 
were not categorized so as to avoid losing information unnecessarily. Non-linear effects 
of continuous predictors were explored using multiple fractional polynomials (MFPs), 
allowing for easier calculation of risk probabilities while being less prone to over-fitting 
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than some alternative methods. Continuous variables were centred near their approximate 
mean to facilitate the interpretation of results, graphing of associated risk, and preparing 
individual risk values.  
3.2.5.2 Variable Selection 
 Beginning with the full set of candidate predictors, model reduction was 
accomplished through “intelligent” variable selection. This method removed variables 
based on their relative contribution to the model predictive performance – how they 
affected the c-statistic – rather than an arbitrary p-value cut point. Variables were only be 
removed from the model if they demonstrated a small or implausible effect in the model, 
or if their contribution to model prediction was minimal (Steyerberg, 2009). Reducing the 
number of variables in the model, and limiting this model to those that may be more 
readily available, reduced the likelihood of over-fitting to this sample and also made the 
model more feasible for public and clinical use (Steyerberg, 2009). 
Interactions that had a plausible association with lung cancer risk, such as gender-
race and gender-alcohol consumption, were evaluated using a Wald test for contribution 
to model performance. Collinearity was first analyzed through a correlation matrix, 
inputting all variables to be included in the model. Associations between categorical 
variables were further analysed using Pearson’s chi-square analysis. Any predictors that 
demonstrated a strong degree of correlation were evaluated. Potential combination into a 
new variable, separate evaluation, or removal from the model entirely were considered 
depending on the nature of the variable (Steyerberg, 2009). 
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3.2.5.3 Assumption Checking 
 One assumption that must be satisfied to indicate that the model has been 
adequately fitted is the proportional hazards assumption – stating that the hazard function 
for two individuals will remain constant over time (Cox, 1972; Ng’andu, 1997). There are 
a number of different ways that the proportional hazards assumption can be tested, 
however in this study we used Schoenfeld residuals as a function of time – accomplished 
using the “estat phtest” function in Stata (Cleves, Gould, Gutierrez, & Marchenko, 
2008). Assessment was accomplished through the graphical interpretation of the scaled 
Schoenfeld residuals plotted against time, with a slope of zero indicating that the hazards 
are proportional and the assumption is satisfied (Cleves et al., 2008).  
3.2.6 Model Evaluation 
3.2.6.1 Discrimination 
 The importance of discrimination as an evaluator of a models predictive 
performance was discussed previously in this thesis. Since this model was created using 
Cox survival analysis, the c-statistic – analogous for the AUC – was used to evaluate 
discrimination (Harrell, 2001). The c-statistic for the full model was estimated as a mean 
of each of the 10 multiple imputation models. A comparable logistic model was created 
for comparison purposes. Discrimination was categorized using Hosmer-Lemeshow AUC 
cut-points (Hosmer & Lemeshow, 2000), with a score of 0.7 or greater corresponding to 
good-to-excellent discrimination, and between 0.6 and 0.7 corresponding to adequate 
discrimination. The aforementioned Tammemagi et al. PLCOall2014 model was tested 
only on the never-smoking cohort, and performed with an AUC of 0.662 (Tammemagi et 
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al., 2014). This AUC will provide a benchmark for which to improve upon in the current 
study. 
3.2.6.2 Calibration 
 The common methods for evaluating calibration were also discussed previously in 
this thesis. This study proposed to use three methods: the Spiegelhalter’s z-statistic 
component of the Brier score (Brier, 1950), visual interpretation using calibration plots 
(predicted versus actual probability) (Steyerberg, 2009), and the mean and 90th percentile 
absolute error – which has been used in previous predictive studies (Tammemagi et al., 
2011, 2014). There is no accepted range for a “good” Brier score, however a lower score 
indicates better calibration. Calibration plots were evaluated against a slope of 1 (perfect 
calibration) while the mean and 90th percentile errors were compared to the Tammemagi 
et al. (Tammemagi et al., 2014) values for the never-smoker cohort (mean=0.0002, 90th 
percentile=0.0003).  
3.2.6.3 Internal Validation 
 In order to maximize the data available for model building, the full control and 
intervention arms were used for training. Thus, there was no portion of the data set aside 
for validation as had previously been commonplace in predictive studies (Moons et al., 
2012). Instead, bootstrapping validation techniques were used. Bootstrapping involves 
the repeated sampling with replacement of the original study data, creating numerous 
bootstrap samples with which to estimate the overall model performance corrected for 
over-fitting (Steyerberg, 2009). In this analysis, 2000-times bootstrap resamplings were 
performed using R-statistical software, specifically Harrell’s rms package (Harrell, 2014).  
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3.2.7 Predicted Probabilities 
 In order to present the results from the model in a meaningful and clinically 
relevant way, predicted probabilities were constructed for all individuals in the sample for 
whom data were available. These are often presented as the probability of developing 
lung cancer within a set time frame – one year, five years, ten years, etc., and provide a 
useful and easily understood tool for clinicians (Moons et al., 2012). In Cox models, the 
predicted probabilities are calculated through the individual variable values – an 
individual’s age, for example – multiplied by the coefficient determined by the model. 
The sum of all of the predictor values provides the raw risk score, which must then be 
translated into an overall probability by incorporating the baseline survivor function – the 
probability of an individual with values of x for all the predictors developing the disease 
at a given point in time – x being the mean or proportion for each variable (Vach, 2013; 
Woodward, 2013). For this model, predicted probabilities were calculated for six-year 
lung cancer incidence. Six-year probabilities were calculated to compare to the 
Tammemagi et al. PLCO models (Tammemagi et al., 2011, 2014).  
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CHAPTER IV: RESULTS 
4.1 Population Characteristics 
 Characteristics of the 69,272 never-smokers in the PLCO control and screening 
arms are described in Table 3. Information for this table consists of baseline 
characteristics for individuals, in addition to responses from the Dietary and 
Supplemental questionnaires for available participants. The participants were divided into 
two groups, those who never experienced a lung cancer diagnosis at any point during 
follow-up (n=68,996), and those that did (n=276). The overall incidence of lung cancer 
amongst PLCO never-smokers was 35.4 cases/100,000py over the complete follow-up 
(median = 12.5 years). Differences between groups were evaluated using the Wilcoxon 
rank-sum test for non-normally distributed continuous variables (age, BMI), chi-square 
test for categorical variables, and Fishers exact test for categorical variables with cells 
containing five or fewer individuals. There were significant differences seen between 
groups for age, BMI, personal history of cancer, family history of lung cancer, and CXR 
in the past three years. No outliers were detected or removed, a product of the rigorous 
follow-up and data management procedures of the PLCO data set. 
 Univariate hazard ratios and 95% confidence intervals are presented for each 
variable, estimating the six-year risk of developing lung cancer. This univariate analysis 
was also used to guide variable selection for model building, which is discussed in a later 
section. The strongest significant effect was seen with previous history of cancer 
(HR=2.57, 95% CI 1.25-5.28). A larger effect was seen with SHS exposure as an adult, 
however this was non-significant (HR=3.81, 95% CI 0.95-15.23). 
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Table 3. Characteristics of PLCO never-smoker population (N=69 272) 
Variable No lung cancer (n= 68 996) 
Lung cancer 
(n= 276) P 
Number of 
Missing 
Univariate Hazard Ratio  
(95% CI; p-value) 
Sociodemographic      
Age, mean (SD), years 62.86 (5.43) 65.56 (5.21) <0.001* 0 1.10 (1.07-1.14; <0.001) 
Gender, number   0.688 † 0 1.25female vs male (0.84-1.85; 0.276) 
    Female 41 183 (99.59%) 172 (0.41%)    
    Male 26 813 (99.61%) 104 (0.39%)    
Race/ethnicity, number   0.798‡ 23  
    White 61 067 (99.60%) 248 (0.40%)   1.0 
    Black 3 118 (99.71%) 9 (0.29%)   0.39 (0.10-1.57; 0.184) 
    Hispanic 1 177 (99.75%) 3 (0.25%)   ---- 
    Asian 3 101 (99.55%) 14 (0.45%)   0.77 (0.28-2.09; 0.607) 
    American Indian 361 (99.45%) 2 (0.55%)   1.67 (2.33-11.99; 0.609) 
    Pacific Islander 149 (100%) 0 (0%)   ---- 
Education, number   0.439† 177 0.89 (0.80-1.01; 0.061) 
    Less than HS 3 998 (99.45%) 22 (0.55%)    
    HS graduate 16 505 (99.58%) 70 (0.42%)    
    Post-HS training 7 867 (99.57%) 34 (0.43%)    
    Some college 13 885 (99.63%) 52 (0.37%)    
    College graduate 12 102 (99.68%) 39 (0.32%)    
    Postgraduate 14 465 (99.61%) 56 (0.39%)    
Medical history      
Body mass index, mean (SD), kg/m2 27.24 (4.99) 26.63 (4.78) 0.036* 1048 0.97 (0.93-1.01; 0.184) 
Personal history of cancer, number   0.017† 0 2.57 (1.25-5.28; 0.010) 
    Absent 66 942 (99.61%) 261 (0.39%)    
    Present 2 054 (99.28%) 15 (0.72%)    
Family history of lung cancer, number   0.037‡ 2210 1.57 (0.97-2.54; 0.065) 
    Absent 60 234 (99.62%) 230 (0.38%)    
    One relative 6 235 (99.52%) 30 (0.48%)    
    Two or more  329 (98.80%) 4 (1.20%)     
(continued on the following page) 
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Variable No lung cancer (n= 68 996) 
Lung cancer 
(n= 276) P 
Number of 
Missing 
Univariate Hazard Ratio  
(95% CI; p-value) 
Ever diagnosed with COPD?   0.109‡ 0 073 (0.23-2.30; 0.588) 
    No 66 404 (99.59%) 271 (0.41%)    
    Yes 2 592 (99.81%) 5 (0.19%)    
Chest x-ray in the past 3 years, number   0.009† 2987 1.85 (1.21-2.83; 0.005) 
    None 32 246 (99.65%) 112 (0.35%)    
    One 21 655 (99.60%) 87 (0.40%)    
    Two or more 12 120 (99.47%) 65 (0.53%)    
Exposure history      
Regular ibuprofen use, past 12 months   0.031† 348 0.97 (0.64-1.47; 0.875) 
     No 49 478 (99.57%) 212 (0.43%)    
     Yes 19 174 (99.69%) 60 (0.31%)    
Drinks per week, number   0.316† 14 140 0.94 (0.78-1.12; 0.457) 
    None 19 548 (99.65%) 69 (0.35%)    
    Less than one 15 595 (99.68%) 50 (0.32%)    
    Between 1 and 3 7 967 (99.61%) 31 (0.39%)    
    Between 3 and 7 5 552 (99.69%) 17 (0.31%)    
    Between 7 and 14 4 135 (99.73%) 11 (0.27%)    
    14 or more 2 144 (99.40%) 13 (0.60%)    
Live with a smoker as an adult, number   0.297† 31 762 3.81 (0.95-15.23; 0.059) 
    No 33 091 (99.80%) 66 (0.20%)    
    Yes 4 341 (99.72%) 12 (0.28%)    
Live with a smoker as a child, number   0.338† 31 940 0.92 (0.22-3.83; 0.854) 
    No 22 508 (99.78%) 50 (0.22%)    
    Yes 14 748 (99.82%) 26 (0.18%)    
Work with a smoker as an adult, number   0.183† 31 793 2.34 (0.49-11.29; 0.698) 
    No 33 342 (99.81%) 65 (0.19%)    
    Yes 4 060 (99.71%) 12 (0.29%)    
* P-value by Wilcoxon rank-sum test 
† P-value by chi-square test 
‡ P-value by Fishers exact test 
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4.2 Predictive Model in PLCO Never-smokers 
 For the final predictive model, beta-coefficients and hazard ratios were estimated 
using the 10-times multiple imputation (full) model, and the PLCO never-smoker 
population (n=68,735).  Univariate analysis (Table 3) was used to help select candidate 
predictors, and final variable selection was based on a combination of statistical 
significance (p<0.3), contribution to model performance, and plausibility of the 
relationship between predictor and outcome. In addition to the 10-times multiple 
imputation model, a completed cases model (n=34,355) was created for comparison using 
only non-imputed data. An overview of both the multiple imputation and completed cases 
models is presented in Table 4.  
 In the full model, lung cancer risk increased with increasing age, lower BMI and 
lower education level. Furthermore, having a previous personal history of any cancer, 
more than one CXR in the past three years, and living with a smoker as an adult were all 
associated with an increased risk of lung cancer. Having one first-degree relative with a 
history of lung cancer was associated with an increased risk (HR=1.336, 95% CI=0.745-
2.128), while having two or more first-degree relatives was associated with a further 
increased risk (HR=3.522, 95% CI=0.865-14.354). The low number of events in the 
completed cases model indicates the necessity of multiple imputations.	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Table 4. Multiple Imputation and Completed Cases Cox Proportional Hazards models, six-year follow-up. 
	  
*Mean of 10 imputations, range provided instead of 95% CI 
† 2000x bootstrap optimism correction using Harrell’s rms package in R software 
‡1000x bootstrap corrected for optimism 
§ Calculated using Stata “comproc” function and Cox model-estimated probabilities 
║ Calculated using representative imputed dataset (Imputation #6) 
¶ Brier score calculated using six-year lung cancer incidence and model-estimated six-year risk 
 Multiple Imputation Model (n = 68 735) Complete Cases Model (n= 34 355) 
Variable Hazard Ratio (95% CI; p-value) Hazard Ratio (95% CI; p-value) 
Lung cancer cases, n 109 9 
Age, per year 1.095 (1.057-1.135;  <0.001) 1.039 (0.917-1.176; 0.549) 
Body mass index, per kg/m2 0.972 (0.932-1.013; 0.184) 0.941 (0.803-1.102; 0.451) 
Education, per 1 of 6 levels change 0.935 (0.829-1.054; 0.272) 1.106 (0.719-1.699; 0.647) 
Personal history of cancer, yes vs no 1.909 (0.752-4.850; 0.173) ---- 
Family history of lung cancer   
    No relatives Reference group Reference group 
    One relative 1.336 (0.745-2.128; 0.331) 1.337 (0.164-10.906; 0.787) 
    Two or more relatives 3.522 (0.865-14.354; 0.079) 23.250 (2.823-193.657; 0.003) 
Chest x-ray in the past 3 years, more than 1 vs 1 or fewer 1.554 (1.004-2.408; 0.048) 0.623 (0.077-5.040; 0.657) 
Live with a smoker as an adult, yes vs no 1.262 (0.555-2.872; 0.567) 3.901 (0.936-16.259; 0.062) 
Model Performance   
 Harrell’s c-statistic 0.6840 (0.6770-0.6963)* 0.7059 (0.5052-0.9066) 
    Optimism corrected 0.6645† ---- 
 Area under the curve (AUC) 0.6858 (0.6358-0.7358) § 0.5696 (0.4912-0.6351) §‡ 
 Absolute error   
      Mean 0.0018║ 0.0018 
      90th percentile 0.0027║ 0.0032 
 Brier score 0.0016 ¶ 0.0003 ¶ 
 Spiegelhalters statistic (p-value) 0.9826 >0.999 
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Education level was treated as a continuous variable, due to the relatively 
consistent change in effect between increasing levels. Non-linear effects of continuous 
variables – age and BMI – were investigated using MFPs, however the relationship with 
lung cancer risk remained linear, and thus the variables were only centred at their 
approximate means (62 years and 27 kg/m2 respectively).  
 Variables such as gender, race/ethnicity, lung comorbidities, alcohol 
consumption, amount of self-reported physical activity, SHS exposure in the workplace 
and as a child (<18 years of age), and regular ibuprofen and aspirin use were investigated 
based on suspected association, however they were rejected from the final model due to 
weak, non-significant or implausible effects on lung cancer risk. Interaction terms were 
investigated, however none contributed to model performance while also being a 
plausible relationship. 
4.2.1 Model Evaluation 
Statistics evaluating model performance are presented in Table 4. For the full 
model, a c-statistic was generated from the mean c-statistics for each of the 10 individual 
imputations (c=0.684, range 0.677-0.696). The Cox model performed similarly in male- 
and female-specific populations, with an estimated c-statistic of 0.694 (range 0.686-
0.711) and 0.675 (range 0.669-0.683) respectively. Through internal validation, via 2000-
times bootstrap resampling, an optimism corrected c-statistic was estimated to be 0.665. 
A comparable logistic model, created using the Cox model-estimated six-year risk and 
using six-year lung cancer incidence as the outcome, produced a ROC-AUC of 0.686 
(95% CI 0.636-0.736). These c-statistics and ROC AUCs correspond to fair or adequate 
discrimination, falling just short of what some consider to be good discrimination (>0.7).  
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 Model calibration was evaluated through two methods: mean and 90th percentile 
absolute error, and a calibration plot (observed versus predicted lung cancer 
probabilities). In the full model, the mean and 90th percentile absolute errors were 0.0018 
and 0.0027 respectively (Table 4), which compares favourably to other models 
(Tammemagi et al., 2011). The calibration plot, seen in Figure 1, displays the observed 
and predicted six-year lung cancer probabilities, a lowess curve plotted from these data, 
and a dashed-line displaying a slope of 1.0 (perfect calibration) for reference. Finally, a 
Brier score was calculated to evaluate overall model performance (full model Brier score 
= 0.0016, Spiegelhalter p-value = 0.983). The current model was compared to a close 
approximation of the PLCOall2014 model, as presented in Figure 2. This demonstrated a 
modest, however non-significant improvement in model discrimination. 
 
Figure 1. Calibration plot: observed vs. predicted six-year lung cancer probabilities. 




Figure 2 Comparison of the ROC-AUC for the current model and a close approximation of the 
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4.3 Six-year Predicted Probabilities 
 Predicted probabilities, the model-estimated risk of developing lung cancer in six 
years, were calculated for each individual in the full model sample. The first component 
of this, the baseline survival probability, was determined to be 0.9984 from both an 
actuarial and Kaplan-Meier life table. The actuarial life table is presented in Table 5.  
Table 5. Actuarial life table. Estimating year-to-year probability of remaining lung cancer-free. 
Interval Number at beginning 
Number of 
new cases Number lost 
Survival 
probability 
0 1 69 272 22 589 0.9997 
1 2 68 661 20 473 0.9994 
2 3 68 168 18 542 0.9991 
3 4 67 608 18 547 0.9989 
4 5 67 043 18 602 0.9986 
5 6 66 423 14 639 0.9984 
6 7 65 770 22 700 0.9980 
7 8 65 048 32 753 0.9975 
8 9 64 263 23 1 984 0.9972 
9 10 62 256 21 6 150 0.9968 
10 11 56 085 30 10 299 0.9962 
11 12 45 756 19 9 798 0.9958 
12 13 35 939 19 35 920 0.9947 
 
 The baseline survival probability, when combined with beta-coefficients (equation 
in Table 6) from the full model, produced an algebraic risk calculator for individual six-
year lung cancer risk. The formula for calculating individual risk probabilities is 
displayed in Table 6. 
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Table 6. Algebraic six-year risk probability equation and beta-coefficients for individual predictors. 
Equation 
Probability = 1 – (0.9984e(β1x1+	  β2x2…)+0.021098606))* 
Beta-coefficient (β) x-value (x) 
0.0910496 Age (years) - 62 
-0.0283397 BMI (kg/m2) – 27 
-0.06755 Education level: 
1= less than high school 
2= high school graduate 
3= post high school training 
4= some college 
5= college graduate 
6= postgraduate 
0.6467674 Previous history of cancer: 
0= no 
1= yes 
0.2904569 Family history of lung cancer: 
0= no relatives, or more than one 
1= one relative 
1.259542 Family history of lung cancer: 
0= one or fewer relatives 
1= two or more relatives 
0.4414639 CXR in the past three years: 
0= one or fewer occasion 
1= more than one occasion 
0.2333267 Lived with a smoker as an adult (>18): 
0= no 
1= yes 
* Equation adapted from Epidemiology: Study Design and Data Analysis, p. 898 (Woodward, 2013) 
0.021098606 represents mean or proportion of each variable multiplied by respective beta-coefficient 
 
 For the full model sample, the mean predicted risk was 0.19%, while the highest 
risk achieved by any individual was 3.42%. The highest risk individual in this population 
was a 73-year old college graduate, with a BMI of 30.8kg/m2, previous personal history 
of cancer, multiple first-degree family members with lung cancer, and multiple CXRs in 
the past three years. They had no response to whether they lived with a smoker as an 
adult. The distribution of the predicted risk values is presented in Figure 3. The model 
predicted six-year lung cancer risk, divided into approximately equal sized deciles, is 
	   	   	  	   	  69	  
presented in Table 7. This table demonstrates a higher predicted risk of lung cancer in the 
higher risk deciles, corresponding to an increased incidence. 
Table 7. Deciles of model-predicted six-year lung cancer risk with accompanying observed lung 















1 6 907 4 0.06% 0.06% 
2 6 903 3 0.04% 0.08% 
3 6 905 5 0.07% 0.10% 
4 6 904 5 0.07% 0.11% 
5 6 905 14 0.20% 0.14% 
6 6 905 6 0.09% 0.16% 
7 6 904 7 0.10% 0.20% 
8 6 905 15 0.22% 0.25% 
9 6 905 20 0.29% 0.31% 
10 6 904 30 0.43% 0.52% 
 
4.3.1 Comparison to Established Screening Criteria 
 The utility of the full model as a practical screening selection tool was evaluating 
by comparing it to the suggested risk cut-point from the PLCOm2012 model (risk ≥1.51%) 
(Tammemagi et al., 2013, 2014). Applying the PLCOm2012 criteria – with the full model 
derived six-year risk score - to the PLCO never-smoker population, results in 35 
individuals (0.05% of PLCO never-smokers) being recommended for further screening. 
Of these 35 individuals, none received a lung cancer diagnosis within six years of follow-
up. 
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4.4. Assumption Checking 
 The proportional hazards assumptions was evaluated using both the phtest 
function in Stata, as well as through the examination of Schoenfeld residual plots for each 
individual predictor. Based on the phtest, every variable passed the proportionality 
assumption (p>0.05), while the full model passed the Global test (p=0.7774), indicating a 
hazard function parallel with baseline over time. Complete results from the proportional 
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Model-estimated Six-year Lung Cancer Risk
Figure 3. Distribution of model-estimated six-year lung cancer risk for full model sample. 
Figure created through kdensity function in Stata 13 displaying kernel density of model-
estimated probability. 
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Table 8. Results of the proportional hazards test, for both individual level variables and full model. 
Variable P-value 
Age (centred at 62years) 0.2470 
BMI (centred at 27kg/m2) 0.4401 
Education level 0.1030 
Previous history of cancer 0.7791 
Family history of lung cancer  
     One first degree relative 0.4147 
     Two or more first degree relatives 0.9068 
Chest X-ray in past 3 years 0.9904 
Lived with a smoker as an adult 0.8885 
Global test 0.7774 
 
 To further ensure that the proportional hazards assumption was met, visual 
examination of each Schoenfeld residual plot was performed. Through this examination, 
each variable appeared to have a residual slope of approximately zero, indicating 
proportionality. As an example, the Schoenfeld residual plot of the variable age (centred 
on 62 years) appears in Figure 4. 
 
Figure 4. Schoenfeld residual plot of age (centred on 62 years) over the length of study follow-up. A 
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CHAPTER V: DISCUSSION 
5.1 Population Characteristics 
 The PLCO study population was selected to attempt to be representative of the 
general US population in terms of gender distribution and minority representation, while 
the age range of 55-74 years at recruitment was designed to encompass those at the 
higher risk of developing one of the PLCO cancers (Prorok et al., 2000).  
 The selected age range was consistent with what has since been established as 
“high risk” for lung cancer (Aberle et al., 2011). Furthermore, the average age of those 
with incident lung cancer cases in the never-smoker sample was 65.6 years (Table 3), 
which is consistent with the reported never-smoker mean of 63.5 years (Nordquist et al., 
2004). The age range of this study population is consistent with the lower bounds of the 
recommended screening age range, while participants are able to age into the upper range 
(80 years) during follow-up (Humphrey et al., 2013). The PLCO never-smokers are also 
predominately female (59.7%), however this is consistent with what is known about 
never-smokers, especially among older populations (Samet et al., 2009). 
 While minority representation was sought in “appropriate numbers” (Prorok et al., 
2000), the never-smoker cohort appears to be disproportionately white. In total, 
approximately 88% of the study sample identified as a non-Hispanic white, while Asian 
and black participants represented only 4% of the population each, and Hispanics 
represented less than 2% (Table 3). This differs greatly from the US population, which is 
approximately 64% white, 16% Hispanic, 4.6% Asian, and 12.3% black (United States 
Census Bureau, 2013). The under-representation of minorities in the PLCO population 
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resulted in an inability to properly evaluate racial differences and risk of developing lung 
cancer, which will be discussed in the forthcoming limitations section. 
 It has been suggested in previous studies that the PLCO population is more 
affluent than the general US population (Tammemagi et al., 2011), and this is further 
demonstrated through the education attainment of this study sample. The PLCO never-
smoker population were more likely to have obtained a Masters or Doctoral degree (21% 
vs. 11% in the US between the ages of 55-74) (United States Census Bureau, 2014), and 
less likely to have not completed high school (5.7% vs. 18% in the US between the ages 
of 55-74) (United States Census Bureau, 2014). The misrepresentation of the general 
population presents potential limitations to the current study, which will be discussed. 
5.2 Predictors of Lung Cancer Risk 
5.2.1 Age 
 As was expected, age was a statistically significant predictor of lung cancer risk in 
never-smokers (p<0.001). It has been described as the most consistent and important 
predictor of LCINS risk, as it represents both an accumulation of lifetime exposures, and 
an increased likelihood of genetic mutation (McCarthy et al., 2012). The effect per year 
increase was consistent with what was found in previous lung cancer risk prediction 
models (HR=1.095 per year, 95% CI 1.057-1.135), indicating a consistent effect in both 
ever- and never-smokers (Tammemagi et al., 2013). Unlike other models (Tammemagi et 
al., 2011), the age-risk relationship was most accurately modeled linearly, with the 
baseline risk centred at the mean age of 62 years.  
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5.2.2 Body Mass Index 
 Increasing BMI has previously been shown to have a protective effect on lung 
cancer risk, however this relationship was suspected to be due to active smokers having a 
lower BMI (Renehan et al., 2008). In the large meta-analysis by Renehan et al., a relative 
risk of 0.76 was seen for a 5kg/m2 increase in BMI, across all smoking strata. However, 
when limited to never-smokers, this protective effect became lessened, and non-
significant. Separate studies have shown a non-significant increase in risk associated with 
higher BMI in never-smokers, indicating that smoking status may have a confounding 
effect (Kabat et al., 2007; Renehan et al., 2008). 
 This study demonstrated a non-significant protective effect of increasing BMI, 
with a hazard ratio of 0.972 (p=0.184) per one unit increase. While this non-significant 
effect is consistent with what has been shown in never-smoker populations, it is also 
nearly identical to the odds ratio produced in the PLCOm2012 model (OR=0.973, 95% CI 
0.955-0.991), indicating similar BMI-risk relationships between both PLCO ever- and 
never-smokers (Tammemagi et al., 2013). As with age, nonlinear effects were evaluated, 
but the most accurate relationship remained linear – consistent with previous models 
(Tammemagi et al., 2011, 2013). 
5.2.3 Education Level 
 In this study, consistent with other predictive models using the PLCO population, 
level of educational attainment was used as a surrogate for SES (Tammemagi et al., 
2011). Higher SES, and by extension higher educational attainment, has consistently 
demonstrated protective effects for lung cancer risk compared to individuals with lower 
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SES/education (Sidorchuk et al., 2009). The effect of increasing education levels was 
consistent between this study and previous PLCO-derived models, indicating that the 
effect of achieving a higher education level is independent of smoking status 
(Tammemagi et al., 2013). A benefit of the PLCO population having a large number of 
highly educated participants is a large sample size across each of the education groups. 
This allowed for a more accurate estimation of risk with increasing education level, and 
thus a better understanding of progressively lower risk with increasing education 
attainment. However, a drawback of this is that there are fewer than expected low 
education individuals, providing less accurate estimates of the highest risk groups. 
5.2.4 Personal History of Cancer 
 Given the exclusion criteria of the PLCO study – individuals with prostate, lung, 
colorectal, or ovarian cancer, as well as those currently undergoing any cancer treatment 
– there were limitations on participants who had a previous personal history of cancer 
(National Cancer Institute, 2014; Prorok et al., 2000). As such, the majority of previous 
cancers in this study were breast cancer. With regards to breast cancer, it is thought that 
radiation therapy as treatment rather than genetic disposition is the likely cause of future 
lung cancer (Bevers, 2014).  
 Findings from this study were consistent with those of Hodgson et al. (2014) and 
Neugut et al. (1994), which estimated a relative risk of future lung cancer of between 1.5-
3 for women with breast cancer compared to those without. Furthermore, the hazard ratio 
obtained by this model was consistent with the effect in the PLCOm2012 (HR=1.909 
compared to OR=1.582 in PLCOm2012) (Tammemagi et al., 2013). Previous history of 
cancer demonstrated the second highest individual risk contribution (behind only multiple 
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first degree relatives with lung cancer), however this estimate had a wide confidence 
interval due to a relatively low number of positive cases, which in part is due to the 
aforementioned PLCO exclusion criteria.  
5.2.5 Family History of Lung Cancer 
 The largest single effect estimate in this model is having two or more first-degree 
relatives with lung cancer (HR=3.522, 95% CI 0.658-14.354). Family history has been 
hypothesized to be synergistic with smoking status, as studies have shown an increase 
effect estimate in ever-smoker and combined populations compared to never-smokers 
(Lissowska et al., 2010). Family history has been well established as a predictor, both in 
terms of immediate family members, and through heritable genetic mutations (Brennan et 
al., 2011). While there are several loci identified that are associated with increased lung 
cancer risk, these have not been shown to improve prediction beyond family history (Li et 
al., 2012). Due to the limited availability and practicality of GWAS data, current models 
limit heritable cancer risk to family history within first-degree relatives, with risk 
estimates in ever-smoker models consistent with literature (Lissowska et al., 2010; 
Tammemagi et al., 2013).  
 The use of a multilevel categorical predictor for family history (no relatives, one 
relative, two or more relatives) was similar to that by Spitz et al. (2007). While the 
sample size is small at the two or more level, the hazard ratio is significantly higher than 
the single-relative level, providing evidence of a dose-response relationship regarding 
LCINS risk.  
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5.2.6 Chest X-ray in the Past Three Years 
 Previous CXR serves as a risk factor for lung cancer likely as a result of the 
diagnostic workup associated with various inflammatory lung diseases, which have been 
shown to increase the risk of developing lung cancer (Fitzpatrick, 2001). There is little in 
literature to suggest that receiving an CXR would be a major contributor to lung cancer, 
with an estimated 0.1% and 0.5% attributable risk of lung cancer associated with a single 
diagnostic X-ray in males and females respectively (Berrington de González & Darby, 
2004). Nonetheless, multilevel categorical predictors regarding CXR exposure have been 
used in previous risk prediction models (Tammemagi et al., 2011), so there was precedent 
for inclusion in this study. Unlike previous models, receiving one CXR was combined 
with no exposure, as there was no risk difference between the two groups. Thus, the only 
increased risk in never-smokers was associated with receiving multiple CXRs in the three 
years prior to baseline. This served as a strong predictor, and one of the few significant 
even at a 5% significance level in the full model. 
5.2.7 Living with a Smoker as an Adult 
 Secondhand smoke exposure has long been established as one of the most 
consistent predictors of LCINS risk (USDHHS, 2006). The estimated effect of living with 
a smoker as an adult (household SHS) in this study (HR=1.26, 95% CI 0.56-2.87) fell 
within the range provided by the United States Surgeon General – a relative risk of 
between 1.20 and 1.29 (USDHHS, 2006). This means that, despite the high amount of 
imputed data for this SHS variable, the overall effect estimate remained within a 
plausible range. One limitation of the PLCO supplemental data collection was the lack of 
recorded exposure duration for SHS. This meant that the demonstrated three-times 
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increased risk with heightened exposure – as established in the US Surgeon General’s 
report - was undeterminable in this study, leading to a potential underestimation of SHS 
household risk for some individuals (USDHHS, 2006). 
5.2.8 Suspected Risk Factors Not Included 
 There were a number of established LCINS risk factors, that have been discussed 
in depth in literature, that were not included in the final model despite availability in the 
PLCO dataset. First, SHS exposure in the workplace – which was variable in risk but 
generally similar to household exposure – demonstrated a protective effect when entered 
into the full Cox model. This violated one of the conditions for variable selection, the 
need for a plausible effect consistent with what is already known, and thus was not 
included. A similar phenomenon was noticed with the lung comorbidity variable, which 
primarily consisted of cases of COPD. While COPD is thought to occur most often only 
in ever-smokers, there were cases amongst the never-smokers in the PLCO dataset, and 
inflammatory lung diseases had been shown to be associated with increased lung cancer 
risk (Fitzpatrick, 2001). A history of COPD has shown good predictive ability in models 
of ever-smokers (Tammemagi et al., 2011, 2013), so there was reason to believe it would 
be associated with increased risk in never-smokers as well. It instead showed a strong 
protective effect, leading to its removal from the final model for violating one of the 
necessary inclusion criteria.   
 A number of other potential predictors were not included due to a failure to 
improve prediction, a null risk estimate, or a greatly non-significant p-value. Among the 
variables that fit this description were: gender, race, ibuprofen and aspirin usage, alcohol 
consumption, and variables pertaining to physical activity levels and dietary intake. 
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Furthermore, a number of predictors could not be included due to unavailable data in the 
PLCO dataset. This will be discussed in the limitations section. 
5.3 Model Performance 
 This study developed a model with fair or adequate discrimination (optimism 
corrected c-statistic= 0.6645, AUC=0.6858), falling short of the cut-point for what is 
considered good discrimination (Hosmer & Lemeshow, 2000). When compared to the 
best ever-smoker models developed in the same dataset, PLCOm2011 and PLCOm2012, this 
model falls well short (AUC= 0.809 and 0.803 respectively) (Tammemagi et al., 2011, 
2013). Despite this, the current model achieves a modest improvement over the adapted 
PLCOall2014 model limited to never-smokers (AUC=0.662) (Figure 2) demonstrating that 
developing a model amongst never-smokers performs better than a successful ever-
smoker model including a population of never-smokers (Tammemagi et al., 2014). 
 The current model performs better than the Spitz model when limited to the 
never-smoker population (c-statistic= 0.57) (Spitz et al., 2007). Model calibration is 
worse than in the PLCOall2014 model, as well as the original PLCOm2011 model 
(Tammemagi et al., 2011, 2014), but still represents good calibration based on the mean 
and 90th percentile absolute errors, and non-significant Spiegelhalter’s statistic. Despite 
this, model calibration worsens above a six-year probability of 0.01, indicating that 
calibration may not be good at any decision-making threshold. This indicates that while it 
does not achieve the performance of other PLCO models, it does compare well to other 
never-smoker models and even some ever- and current-smoker models.  
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5.3.1 Is This Model Suitable for Never-smoker Risk Prediction? 
 The goal of this thesis was to develop a risk prediction model for never-smokers 
capable of accurate individual-level risk prediction, similar to the Tammemagi PLCO 
models (Tammemagi et al., 2014). Which begs the question: does this model achieve the 
goal of being able to predict lung cancer accurately in never-smokers? According to 
Harrell (2001), who states an AUC of greater than 0.8 is required for individual-level 
prediction, this model is not capable.  
 In a more practical sense, it is important to identify how many never-smokers 
would be identified for screening using this model, given that none are screened using 
current criteria (USDHHS, 2006). When the PLCOm2012>0.0151 risk probability - which 
was proven to be more efficient in identifying individuals for screening- is applied to this 
model, a total of 35 individuals are selected (Tammemagi et al., 2014). This means that 
out of the 69,272 never-smokers in the PLCO population, only 35 (0.0005%) would be 
selecting for screening, indicating a very low number of qualifying never-smokers. 
Furthermore, of these 35 individuals that would be selected for screening based on their 
six-year predicted risk, none actually developed lung cancer within the first six years of 
follow-up. Unlike the PLCOall2014 model, the highest achieved risk for a never-smoker in 
this model was 0.0342, however, since these “high-risk” individuals did not get cancer, 
screening them would in fact be an inefficient use of resources. 
 Lowering the risk threshold to capture more LCINS cases is not a feasible option, 
as the vast majority of cases are clustered in the 0-0.4% six-year risk range, along with 
the majority of the never-smoker population. This clustering of risk scores is likely due to 
relatively few never-smokers having the traits that most greatly increase risk (multiple 
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relative family history, multiple CXR exposure, personal history of cancer), and is also 
likely representative of the true nature of lung cancer risk as exposure to known risk 
factors is low for never-smokers. Low exposure frequency, coupled with low six-year 
lung cancer incidence, results in few high-risk individuals and few lung cancers. 
5.3.2 Improving LCINS Risk Prediction 
 The inability of this model, and all never-smoker risk prediction models, to 
achieve high discrimination leads to the question: what needs to be done to develop a 
good risk prediction model, and why does the never-smoker population differ from 
smokers with regards to predictive success? The answer is two-fold; the predictors that 
were strongest in never-smokers were also fairly rare among the population, leading to 
few people achieving high risk, and also the lack of a predictor that is as strongly tied to 
lung cancer risk as smoking is in current and former smokers. Even the strongest 
predictor in this model (multiple relative family history, HR= 3.522) is much weaker than 
being a current active smoker, which has been shown to increase lung cancer risk by 10-
20-times (Clément-Duchêne et al., 2010).  
 In order to improve LCINS prediction, it is necessary to identify predictors similar 
to active smoking. Among the candidates would be a trio of loci identified via GWAS: 
5p15, 6p21, and 15q25 (Brennan et al., 2011; Rudin et al., 2009). The inheritance of risk 
alleles on these loci has been associated with an 80% increased risk, which is much lower 
than the risk associated with active smoking (Brennan et al., 2011). To date, including 
GWAS data in lung cancer models has not improved prediction (Li et al., 2012). While it 
is very unlikely that any single predictor would improve never-smoker prediction, a 
combination of GWAS and biomarker data could lead to improved prediction. A 
	   	   	  	   	  82	  
drawback of using GWAS data, as is also the case with clinical biomarker data, is that it 
requires additional testing or sequencing, and thus reduces the clinical relevancy and 
usefulness (Tammemagi, 2015). An appeal to this model, along with others (Tammemagi 
et al., 2013), is that they can be carried out by public health officials using readily 
available data, or data that can easily be obtained from individuals. 
5.4 Limitations 
5.4.1 Unavailable Variables 
 While there were many suspected risk factors for LCINS described in the 
literature, many of the strongest ones were not available in the PLCO dataset. Missing 
information that could potentially be valuable includes environmental exposures, 
occupational exposures, and residential radon exposure. There is some precedent for the 
use of these exposures in lung cancer predictive modeling, as Spitz et al. used self-
reported history for select exposures while both Spitz et al. and Cassidy et al. attempted 
to ascertain asbestos exposure through documented workplace history (Cassidy et al., 
2008; Spitz et al., 2007). However – as the authors report – these variables were self-
reported and not validated, and thus subject to misclassification bias (Spitz et al., 2007). 
The asbestos exposure variable used in the model by Cassidy et al. was complex and 
could not be utilized in practice. Furthermore, developing a reliable “occupational risk” 
variable could be a very time consuming process, with a nearly unlimited number of 
potential jobs that would have to be evaluated for potential exposure risk, and categorized 
accordingly. While it would be difficult to develop, an accurate and easily categorized 
occupational exposure variable may have been beneficial to model performance. 
Furthermore, while environmental and residential radon exposures are difficult to 
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measure at an individual level, ecologic measures (urban vs. rural, basement dwelling vs. 
upper-storey, etc.) could have allowed for some investigation of these risk factors. A 
drawback of using these ecologic measures is that these variables would be prone to 
misclassification, and likely provide little utility or in risk prediction or potentially 
worsen predictive performance. Finally, given the restrictions on PLCO inclusion criteria 
(no previous history of PLCO cancers), the risk associated with some of the most 
common types of cancer could not be determined (Prorok et al., 2000). With 13.2% of 
second primary cancers occurring in the same tissue as the original cancer, it is possible 
that having previous lung cancer as a predictor would have strengthened model 
performance (Bevers, 2014).  
 Expanded data on some variables already included in the dataset, such as more 
detailed dose-related SHS exposures, would also have allowed a better understanding of 
individual-level risk. As was mentioned in the US Surgeon General’s report, there was a 
noted dose-response relationship (3x increased risk associated with >4 hours per day 
exposure compared to no exposure) (USDHHS, 2006). Being able to better elucidate this 
relationship among the population could have added to the predictive performance of the 
model by providing a higher-risk group, perhaps further separating cases from non-cases. 
5.4.2 Population Representation 
 As was mentioned in Section 5.1, the PLCO study sample was not completely 
representative of the United States population as a whole. The study sample is 
predominately white and more educated than would be expected by truly random 
sampling (United States Census Bureau, 2013, 2014). As is outlined by Murthy et al. 
(2004), underrepresentation of minorities and lower SES individuals is a recurrent 
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problem in cancer screening trials, likely a product of both selective recruitment and a 
mistrust in the health care system (Murthy et al., 2004). Minimal representation of 
minorities eliminated the possibility of doing race-specific subset models. Given the 
modest performance of this model, the supposed heightened risk of some racial groups, 
and the evidence of good subpopulation-specific versions of other models, it would have 
been beneficial to investigate in this model (Haiman et al., 2006; Tammemagi et al., 
2011; Thun et al., 2008).  
5.4.3 Self-reported Data 
 PLCO data were obtained via self-reported questionnaire, which leads to 
questions about the validity of the responses (Prorok et al., 2000). The responses to this 
questionnaire, especially those pertaining to smoking status, alcohol consumption, dietary 
choices, and physical activity, are subject to social desirability bias (van de Mortel, 
2008). Since participants may be more inclined to respond in a way reflecting societal 
norms or ideals, smoking status and alcohol consumption may be underestimated while 
physical activity and dietary consumption may appear more favourable (van de Mortel, 
2008). This could have led to a washing out of the effects of predictors that were subject 
to social desirability bias, and worsening of model prediction as the true effect of these 
variables on lung cancer risk would not be modeled.  
5.5 Strengths 
 This study had a number of strengths, first of which is the use of the PLCO 
dataset. This is a large, prospective study which contains a large number of never-
smokers. It avoids the limitations of some other lung cancer models, which use case-
	   	   	  	   	  85	  
control data and are often matched based on age, gender, and smoking status (Cassidy et 
al., 2008; Spitz et al., 2007). Using prospective data allowed for use of incidence data, 
which is ideal for risk prediction modeling (Adami et al., 2008; Tammemagi et al., 2011). 
These data are also high-quality, with rigorous follow-up procedures ensuring that data 
were available for nearly all individuals throughout the study process (Prorok et al., 2000; 
Tammemagi et al., 2011). This is the same data source used in other high-performing 
lung cancer risk prediction models, further indicating the usefulness of these data 
(Tammemagi et al., 2011, 2013).  
 Secondly, advanced statistical techniques were used throughout the 
methodological process. First, using multiple imputation allowed for an accurate means 
of estimating missing data, avoided losing observations and outcomes due to the use of 
Supplemental and Dietary data, and thus allowed for the inclusion of SHS and potential 
inclusion of other predictors in the final model. Next, using Cox proportional hazards 
regression allowed for the inclusion of time-to-event data, maximizing the amount of 
information that went into generating risk scores and allowing for multiple follow-up 
periods to be used – although only six-year risk was ultimately included in the final 
model. The use of MFPs allowed for the investigation of non-linear relationships of 
continuous variables, and while the relationship remained linear in the final model, it was 
not simply assumed to be so. Bootstrapping internal validation techniques allowed for 
optimism correction and providing a more realistic estimate of the c-statistic, while also 
allowing for this study to incorporate the full sample into model-building without 
reserving separate training and validation samples. By not adhering to a strict p-value cut-
point (<0.05), and utilizing intelligent variable selection for model building, we avoided 
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missing potentially useful predictors while also ensuring predictors with spurious 
relationships (such as the COPD-risk relationship) were not included in the final model. 
The final model is parsimonious, containing only seven predictors, and thus should be 
easily reproducible if validated in other studies (Harrell et al., 1984; Moons et al., 2012) 
 This study attempted to expand and improve on previous models by investigating 
a number of novel risk factors, based on what is established or suspected in LCINS 
literature. While no predictors were unique specifically to this model, relationships 
between ibuprofen and aspirin use, alcohol consumption, physical activity, female 
hormone usage, and dietary factors – among others – were investigated for their potential 
role in predicting lung cancer. Many of these variables were made possible by the 
inclusion of Supplemental and Dietary Questionnaire data, and the use of multiple 
imputations allowed these variables to be used without a reduction in sample size. Most 
never-smoker models were developed alongside ever- and current-smoker models (Spitz 
et al., 2007) or adapted from existing smoker-developed models (Tammemagi et al., 
2014), and thus this model benefits by being developed in a large population of 
exclusively never-smokers, and using predictors determined from an LCINS-specific 
literature review. 
5.6 Implications 
 Based on the adequate discrimination, and the fact that no lung cancer cases were 
detected amongst the few high-risk individuals identified, this suggests that the current 
model is not suitable for clinical use or individual-level risk prediction in never-smokers. 
Without an overwhelmingly strong predictor, such as smoking intensity and duration in 
smokers, never-smoker prediction appears to be limited to moderate discrimination and 
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population-level prediction at best. This is not to say that never-smokers should not be 
eligible for screening, as 10-15% represents a large amount of lung cancer cases overall, 
only that there needs to be better, more efficient methods for identifying those never-
smokers at high risk.  
5.7 Future Research 
 The most important next step in LCINS research is to identify predictors, similar 
to smoking status, that allow for improved discrimination. A likely candidate is the use of 
genomic data, particularly a select group of genes associated with increased risk amongst 
never-smokers. In addition, biomarkers such as haemoglobin and fasting glucose levels 
have been included in lung cancer prediction models (Tammemagi, 2015), and therefore 
it may be beneficial to investigate their performance in LCINS prediction. However, it is 
also important to be mindful of the practical utility when developing future LCINS 
prediction models, as genomic and biomarker data are not as readily available. Further, 
more practical, areas of future research include the investigation of subpopulations within 
the never-smoker population, particularly specific race groups that may be at higher risk. 
Asian populations have demonstrated a much higher incidence of LCINS than North 
America, or individuals of Asian decent living in North America (Thun et al., 2008), so 
developing a model in this population is of public health importance and it may be 
possible to develop a good prediction model in Asian never-smokers. This could allow 
for the identification of at least some high-risk groups, and potentially lead to screening, 
early detection, and reduced mortality for some of the 10 to 15% of lung cancer cases that 
occur in never-smokers. 
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5.8 Conclusion 
With the success of LDCT screening in improving detection and diagnosis of lung 
cancer (Aberle et al., 2011), specifically in high-risk individuals, it has become 
paramount to develop ways of detecting exactly who constitutes “high-risk”. To date, 
lung cancer risk prediction models have demonstrated a good ability to identify high-risk 
individuals, with recent studies showing more efficient screening identification than the 
United States guidelines (Tammemagi et al., 2014). However, a common theme amongst 
prediction models and screening guidelines is the exclusion of never-smokers from high-
risk groups, despite an estimated 10-15% of lung cancer cases occurring in never-
smokers (Samet et al., 2009). Never-smokers are subject to a different set of lung cancer 
risk factors than their ever-smoking counterparts, and thus require a specifically 
developed model to allow for accurate risk prediction (Sun et al., 2007; Tammemagi et 
al., 2014). Therefore, the aim of this thesis was to develop and validate an accurate risk 
prediction model in never-smokers, with the goal of achieving individual level predictive 
performance. 
 This current model was developed using the same population, and many of the 
same statistical techniques as other high-performing lung cancer models (Tammemagi et 
al., 2011). However, this model does not achieve the same level of predictive 
performance, achieving good calibration and fair to adequate discrimination, and is 
therefore not appropriate for individual-level risk prediction. Despite rigorous statistical 
methodology and the use of high-quality data, this study was not able to develop a model 
in never-smokers with the same capability of ever- and current-smoker models. This 
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study does represent an improvement on existing never-smoker models (Spitz et al., 
2007; Tammemagi et al., 2014) indicating progress in the field of LCINS risk prediction. 	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